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ABSTRACT 
CASPASE-7 LOOP CONFORMATIONS AS A MEANS OF ALLOSTERIC 
CONTROL 
MAY 2011 
WITOLD WITKOWSKI, B.S. COLLEGE OF CHARLESTON 
Ph.D. UNIVERSITY OF MASSACHUSETTS AMHERST 
Directed by: Professor Jeanne A. Hardy 
The caspase family of proteins is critical to biological understanding, because they serve 
as the final arbiters of life and death, being the initiators and executioners of cell death. 
Specifically, caspase-7 plays a key role in apoptosis, however its full complement of 
targets within the cell has not yet been elucidated, nor has its function been targeted by 
drug design efforts. These factors stem from the lack of fundamental understanding of the 
structural dynamics of the protein, including the mobile loops that constitute the active 
site binding groove of caspase-7, and their ability to modulate the function of the protein. 
In this work, we describe the importance of the entire loop bundle for catalysis, 
demonstrate a novel approach for allosteric control using loop movement, develop 
computational methods to engineer a new binding site for an allosteric effector and 
discover a hereunto unseen native disulfide within caspase-7 that may contribute to 
specificity and catalysis. The information obtained within this study is applicable for not 
only the study of caspase-7, but also the greater field of apoptosis research.   
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CHAPTER I 
INTRODUCTION 
The ability to dynamically and independently modulate the function of proteins for either 
elucidative reasons or curative treatments would change the world of medicine. Advances 
in structural biochemistry, combined with novel techniques will allow new problems to 
be tackled. In this work, I present advancements in the field of protein chemistry that 
develop new insights into the role of the loops in caspase-7, and their ability to control 
caspase-7. 
Apoptosis 
For many years, it was tacitly assumed that due to continuous cellular 
proliferation, a mechanism for programmed cell death must exist. Until cell morphologies 
during cell death were rigorously defined, programmed cell death was broadly described 
as coagulative necrosis active site1. The morphological changes in two types of cell 
death, necrosis and apoptosis, lead to the distinction in the classes. During necrosis, cells 
swell and burst, leaving cellular debris, which often results in an inflammatory response. 
Conversely, apoptosing cells shrink, and are rapidly phagocytosed in an orderly fashion. 
Since Kerr and coworkers coined the term apoptosis in their seminal 1972 paper, the 
highly conserved cellular machinery responsible for this ordered process has been 
broadly studied across many organisms, and its evolutionarily conserved pathways have 
been elucidated.  
2 
Apoptosis’ importance to cellular function and organism development cannot be 
understated, its regulation is necessary for both death, and life in cells. Apoptosis is most 
associated with cellular demise, however regulated cell death is necessary for proper 
organism development. For instance, in mice deficient a cell death protein (caspase-3), 
organism death occurs early in embryonic development with an over abundance of 
neuroepithelial cells2. This suggests that cell death is necessary in neurological 
development. In another experiment, irreversible broad spectrum peptidic inhibitors of 
apoptosis were introduced into chicken embryos, and the footpads were studied3. In 
embryos treated with the inhibitors, evidence of interdigital cell death decreased, leaving 
the embryo with webbed feet (Figure 1). The role of apoptosis is not limited to limb 
development, as many have shown that regulated cell death plays a key role in sexual 
differentiation4-7, and terminal cell differentiation. A erythrocyte’s final developmental 
stage involves the loss of organelles and nucleus, but remain viable and continue to 
metabolize; conversely keratinocytes form layers of squamous skin layers at their final 
differentiation stage. These two near end of life or alternate G1 exit stage processes are 
thought to be the result of modified programmed cell death8,9.  
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Figure 1: Inhibition of apoptosis in development.  
Interdigital cell death (dark staining, arrows) is retarded in the presence of apoptotic inhibitors3.  
 
Disorders Associated with Apoptosis 
Apoptosis’s role in the life/death decision is critical, and cellular havoc occurs when 
apoptosis goes wrong. Errors in apoptosis have been linked to many diseases, as the 
delicate life/death balance is disturbed. During cell proliferation, a number of regulators 
and growth factors check the cell cycle to maintain order10. The disease most classically 
associated with down-regulated cell death is cancer. Though there exist many variants of 
malignancy, all stem from a common inability to undergo apoptosis11. Disorders typically 
associated with rapid cell death are heart attacks and stroke.  Notably, these diseases are 
primarily caused by lack of blood flow to the region, leading the affected cells to necrose.  
However, tissue not directly affected by the restricted blood flow, but in the vicinity of 
necrotic tissue has been shown to die by apoptosis12,13, and directly inhibiting apoptosis 
in these cells can limit the damage14. Less obvious diseases such as viral infections and 
their associated cellular processes have also been linked to apoptosis15,16.  
Caspases 
The amazing molecular scale machinery that is responsible for executing the balance of 
life and death in cells are called caspases, from Cysteine-Aspartate-Proteases. The origin 
of caspases and their role in the apoptotic pathway was first reported by Robert Horvitz 
and coworkers, while studying the C. elegans death gene CED-317. Horvitz was 
subsequently awarded the Nobel Prize for the elucidation of the apoptotic pathway. 
Horvitz and coworkers noted a predicted protein sequence similarity between CED-3 and 
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the human and murine interlukin-1" converting enzyme. This enzyme had been 
characterized as a heterodimeric cysteine protease18, and later renamed caspase-1. 
Discovery of other caspases followed soon after, and necessitated the distinction of 
apoptotic caspases (-2, -3, -6, -7, -8, -9, -10) versus inflammatory caspases (-1, -4, -5, -
11, -12, -13, -14) (For review, see19-22).  
 
Figure 2: Differences in intrinsic versus extrinsic caspase activation 
Caspase and thus apoptosis activation can occur either from extrinsic (external) or intrinsic 
(internal) cellular stresses. Based on the nature of the stress, initiation different pathways are 
followed. In the intrinsic pathway, mitochondrial stress causes the release of cytochrome c, which 
triggers the formation of the apoptosome complex, leading to activation of the downstream 
executioner caspases by caspase-9. In the extrinsic pathway, the DISC complex is activated by an 
extracellular signal, which then causes the maturation of caspase-8, which cleaves executioner 
caspases.  
Apoptotic caspases can be classified as either initiator (-2, -8, -9) or executioner (-3, -6, -
7). Like their necrotic cousins, apoptotic caspases are expressed in the cytosol as 
catalytically inactive zymogens, referred to as pro-enzymes. Caspases are expressed as a 
single chain polypepide that requires cleavage for maturation. Broadly described, this 
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single chain is composed of three sections, the N-terminal peptide, large subunit, and 
small subunit. During maturation and activation, the N-terminal peptide is cleaved off, as 
is an inter-subunit linker. The length of the N-terminal peptide and inter-subunit linker 
and the order of cleavage are specific to each caspase. (For review see19)  
The activation of these proteolytic enzymes is cellular stress-dependent and the apoptotic 
pathway which activates the caspases varies depending on the nature of the stress. In the 
extrinsic pathway, an extracellular signal is received by TNF-# (tumor necrosis factor), 
which is spatially associated to procaspase-8 in the DISC (death inducing signal 
complex). This signal causes the recruitment of procaspase-8 to the complex and leads to 
the activation of pro-caspase-8. The activation of procaspase-8 is believed to be caused 
by auto-processing23 due to high local concentrations of pro-form caspase-8. Once 
activated, the mature caspase-8 cleaves the downstream or executioner caspases (-3, -6, -
7).  
In the intrinsic pathway, mitochondrial stress induces cytochrome c release, which bind 
to Apaf-1, forcing a conformational change in Apaf-1. This Apaf-1:cytochrome c 
complex facilitates the formation of the apoptosome, which is a heptamer of Apaf-1 and 
cytochrome c in the presence of ATP or dATP24,25. The apoptosome then recruits pro-
caspase-9, and it is thought that the close proximity of two monomers of pro-caspase-9 
induce the intersubunit cleavage activation of caspase-9. Caspase-9, like caspase-8, then 
cleaves the executioner caspases thus activating them. Since the executioner caspases are 
apoptosis pathway independent, their activation typically sounds the death knell for the 
cell. Because of their ability to kill cells or contribute to cell survival, the ability to 
control caspase function is of great utility. In this thesis, we focus on one of the 
6 
executioner caspases, caspase-7, exploring the molecular details of its function and 
engineering a redox sensitive version of caspase-7. 
 
Figure 3: Caspase-7 conformations 
Caspase-7 is expressed as a single chain polypeptide which dimerizes and forms the procaspase-7 
zymogen where loops L2, L3, and L4 are formed but are in a catalytically incompetent 
conformation. Proteolytic processing cleaves the inter-subunit linker on L2 creating the mature 
caspase, which is formed from two small subunits, and two large subunits. Loops L2 and L2’ from 
the opposite side of the dimer are liberated during this cleavage event, but are not in catalytically 
competent conformation. In the active form of caspase-7, binding a covalent inhibitor at the active 
site cysteine promotes the ordering of the active site loop bundle, where L2, L2’, L3 and L4 are 
clearly visible in the crystal structure. Conversely, in the allosterically inhibited form where small 
molecule inhibitors DICA or FICA are bound covalently to cysteines at the dimer interface (C290), 
L2’ adopts a conformation similar to the zymogen form, while L2, L3, and L4 are disordered.  
Executioner caspases are obligate homodimers26,27, each composed of a large and small 
subunit which are formed during cleavage activation by an upstream caspase such as 
caspase-8 or -9. It is notable, however, that caspases recombinantly expressed in E. coli 
self activate by an unknown mechanism. The substrate-binding groove is made up of 
flexible loops on opposite sides of the two-fold symmetrical dimer. The interface of the 
L2’ 
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homodimer of heterodimers creates a large cavity formed by the interface between the 
small subunits composed of anti-parallel " strands (Figure 4). While the crystal structures 
of caspase-328-34 and -635,36,27 exist, caspase-7 has more structural information available 
because the three-dimensional structure of multiple conformations has been solved 
previously by x-ray crystallography37-42. The notable differences between the structures 
lie in the arrangement of the loops that ultimately form the substrate-binding groove. In 
the inactive zymogen caspase, the intersubunit linker that is part of loop L2 is uncleaved, 
lying over the cavity at the interface of the small subunits. (Figure 3) After processing, 
L2 loop is split into L2 and L2’. In the crystal structure of the mature, but catalytically 
incompetent form of caspase-7, loops, L2, L3, and L4 are ordered, but L2’ loops lie over 
the allosteric sites and the substrate binding grooves are not competent to accept 
substrate. When crystallized with a covalently bound tetrapeptide suicide substrate 
(DEVD-CHO), the loops appear fully ordered39, however, the active site geometry of the 
cysteine-histidine dyad is not favorable for catalysis since the catalytic thiol is covalently 
modified by the bound substrate. Binding to the aldehyde containing substrate pushes the 
catalytic thiol out of position for catalysis. The active-site cysteine (Cys186 in caspase-7 
numbering) lies at the base of L2, and the trajectory of the distal end of L2 causes 
interactions between it and L2’ from the opposite side of the dimer. Caspase-7 has also 
been crystallographically observed to adopt an allosterically inhibited conformation when 
small molecules DICA or FICA are bound to cysteine 29042 as represented in Figure 3. In 
this structure, L2’ adopts a loop trajectory similar to that of the procaspase-7 structure or 
the mature apo structure, while loops L2, L3, and L4 are disordered.  
These structural data provided many insights into how the caspase works, and have 
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facilitated study of the active site and the allosteric cavity42. 
 
  
Figure 4: Caspase-7 structure 
Caspase-7 structure is composed of two large subunits (darker color) and two small subunits 
(lighter color) forming a dimer with two fold symmetry. (A) In the active structure of caspase-7, a 
DEVD substrate (spheres) is covalently bound to the active site cysteine, which lies at the base of 
loop L2. Loop L2 and L2’ along with L3 and L4 arrange to form the substrate binding groove. (B) 
In allosterically inhibited structure of caspase-7, L2’ from both sides of the dimer lie over the dimer 
interface in a catalytically inactive form. Additionally, the loops of the active site binding groove 
are disordered (dashes).  
The central cavity formed between the two halves of the homodimer can be harnessed for 
allosteric regulation. In the crystallographic model, allosteric inhibition can be triggered 
by the introduction of a molecule covalently bound to Cys290, which restricts the 
movement of Tyr223 to the up conformation. Tyrosine 223’s rotameric placement is also 
critical for active site conformation stabilization through the steric interference with 
Arg187. In the active form, the arginine 187’s nitrogens are within 4Å of the tyrosine 
ring in the down conformation.  
!"#$$%
!"#$$%
&#'()%
&#'()%
&*%
&*%
&+,%
&+,%
!"#$$%
!"#$$%
&#'()%
&#'()%
&*%
&+%
&+,%
&*%
&+%
&+,%
-./-%
!0123'#3)%
-./-%
!0123'#3)%
4567)% 4$$823)'95#$$:%
;<=9193)>%
9 
 
Figure 5: The caspase-7 allosteric switch 
During allosteric inhibition with a small molecule bound within the cavity at the interface of the 
two small subunits (allosteric cavity), tryrosine 223’s ‘up’ position (magenta) restricts arginine 187 
from adopting the active conformation by forcing arginine 187 and L2 into a conformation not 
amiable to substrate binding. . In the active conformation (green), arginine 187 from L2 adopts a 
conformation that sterically disallows the ‘up’ conformation of tyrosine 223.  
 
This arrangement suggests an interaction between the aromatic ring and the arginine. The 
arginine needs to move toward the cavity to transition from the inactive pro form, to the 
active form. This move is stabilized by the interaction, thus, the tyrosine’s placement is 
critical.  
In addition to R187, positioning of the L2’ loop is essential for allosteric regulation. It 
should be therefore possible to emulate this inhibited conformation of L2’ down over the 
allosteric cavity with a non-covalently bound small molecule, whose contact with the 
cavity will be sufficient to force Tyr223 into a position unfavorable for catalysis, or to 
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block the interaction of Arg187 with Tyr223 which will block the formation of the active 
site. Similarly, a variant of caspase-7 might be designed with restraints on loop 
movement creating an allosterically controllable protease. 
Computational Protein Redesign 
The goal of the Hardy lab is to develop additional vectors of control into proteins in novel 
ways using a rational design approach. By using data from x-ray crystal structures as a 
starting point, computational, rational or directed evolutionary approaches can be 
employed to systematically tune a protein for a desired response. Protein redesign 
whether by computational, rational or directed evolution methods is not a novel idea. 
Early efforts to use computers to augment structural information by way of homology 
modeling started in the early 1980s43,44. Efforts to improve drug-like properties of 
biological molecules have also benefited from computational design45,46. Additionally, 
the use of protein engineering to stabilize complexes for crystallography and functional 
studies is widely employed47,48. Computational protein design and redesign have become 
very powerful tool to study not only novel folds, but also to engineer novel functions. 
Efforts to computationally redesign proteins have met with mixed success49. 
Computational protein design has benefited immensely from recent advances in 
computing power, and thus seminal papers have been published on this topic. Early 
efforts of protein design50-52 focused on a simplified problem that only targeted the 
hydrophobic cores. This pioneering work was necessarily less complex, but nonetheless 
established many algorithms53,54 and prompted work on large combinatorial methods that 
followed55. This work emboldened protein chemists to use computational methods as the 
computational results were becoming more reliable. Two general approaches have been 
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tried in this field, de novo design, and using an existing protein as a scaffold for design. 
Mayo and colleagues have successfully used an automated search method to design a 
novel amino acid sequence that folds similar to a zinc-finger domain in the absence of 
zinc. Baker and colleagues, of Rosetta56 fame, were able to design a globular protein of a 
fold that does not exist in nature in silico, and then solve the crystal structure to 
demonstrate the accuracy of their approach 57. Not satisfied with strictly de novo design, 
Baker and colleagues have successfully reengineered endonuclease specificity58, and built 
an enzyme catalyst for a stereoselective bimolecular Diels-Alder reaction59 using similar 
methods. This substantive success in the field of protein redesign illustrates the 
effectiveness and more importantly, credibility of the method.   
In this thesis, we examine the role of the loops of caspase-7, and their contributions to the 
formation of the substrate-binding pocket. Using these data, we harness the mobility of 
the L2’ loop to engineer a redox activatable caspase-7. Finally, we explore the 
possibilities of allosteric cavity redesign to bind a small molecule using computational 
methods, employing data and knowledge gathered from the investigations of caspase-7.  
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CHAPTER II 
LOOP L2’ IS CRITICAL FOR ACTIVE SITE FORMATION 
The majority of this chapter has been published: Witkowski, Witold. and Hardy, Jeanne 
A. “L2’ loop is critical for caspase-7 active-site formation.” Protein Science, 2009, 18, 
1459-1468. 
Abstract 
The active sites of caspases are composed of four mobile loops. A loop (L2) from one 
half of the dimer interacts with a loop (L2$) from the other half of the dimer to bind 
substrate. In an inactive form, the two L2$ loops form a cross-dimer hydrogen-bond 
network over the dimer interface. Although the L2$ loop has been implicated as playing a 
central role in the formation of the active-site loop bundle, its precise role in catalysis has 
not been shown. A detailed understanding of the active and inactive conformations is 
essential to control the caspase function. We have interrogated the contributions of the 
residues in the L2$ loop to catalytic function and enzyme stability. In wild-type and all 
mutants, active-site binding results in substantial stabilization of the complex. One 
mutation, P214A, is significantly destabilized in the ligand-free conformation, but is as 
stable as wild type when bound to substrate, indicating that caspase-7 rests in different 
conformations in the absence and presence of substrate. Residues K212 and I213 in the 
L2$ loop are shown to be essential for substrate-binding and thus proper catalytic function 
of the caspase. In the crystal structure of the I213A mutant, the void created by side-chain 
deletion is compensated for by rearrangement of tyrosine 211 to fill the void, suggesting 
that the requirements of substrate-binding are sufficiently strong to induce the active 
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conformation. Thus, although the L2$ loop makes no direct contacts with substrate, it is 
essential for buttressing the substrate-binding groove and is central to native catalytic 
efficiency. 
Introduction 
Initiator caspases cleave executioner caspases in two locations to liberate an N-terminal 
propeptide and cleave the intersubunit linker. Executioner procaspases are dimeric so that 
cleavage of the intersubunit linker converts each half of the homodimer into one large 
and one small subunit. Mature caspases then consist of four chains, with two large 
subunits flanking two small subunits in the mature state. Cleavage of the intersubunit 
linker results in the formation of two new termini that function as loops involved in 
substrate binding. The C-terminal end of the large subunit becomes the L2 loop, whereas 
the N-terminal end of the small subunit becomes the L2$ loop. The catalytic cysteine is 
contained on the L2 loops, thus each half of the dimer contains one catalytic site60. The 
catalytic sites are surrounded by extended substrate-binding grooves. Each substrate-
binding groove is composed of three loops (L2, L3, and L4) from one monomer. A fourth 
loop (L2$) from the opposite monomer interacts with L2 to stabilize the substrate-binding 
loop bundle in the active state (Figure 6 A,B).  
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Figure 6: Active caspase-7 
(A) The L2’ loop (colored sticks) is in the ‘‘up’’ position only when substrate binds to the active 
conformation of caspase-7 (PDB ID 1F1J). Residues selected for mutation (K212, orange; I213, 
magenta; P214, blue; V215, green) make interactions with the L2 loop from the opposite half of the 
dimer. The two substrate-binding grooves are bound by inhibitor DEVD (light blue ball-and-
sticks), which is a substrate- mimicking compound. Loops L3 and L4 contribute to the substrate-
binding loop bundle with loops L2 and L2’. (B) Interactions between L20 (colored sticks) and L2 
(gray sticks) stabilize the active form of caspase-7. 
Large conformational changes in L2 and L2$ are associated with the transformation 
between the caspase-7 conformational states, all of which have been structurally 
characterized. When the inactive procaspase-7 zymogen39,41 is cleaved to generate mature 
caspase-7,39 it remains in a conformation that has been observed crystallographically that 
is between active and allosterically inhibited (“semi-active”) until substrate binds, 
inducing the active caspase-7 conformation37,38,61. Caspase-7 can also be allosterically 
inhibited42 by binding of effectors to a cavity at the dimer interface. In the inactive 
procaspase-7 zymogen L2 and L2$ are covalently connected yet they are observed to be 
pointing away from one another, separated by a stretch of disordered residues. This 
conformation is very similar to that observed in the allosterically inhibited state, where 
the L2$ loops interact above the allosteric site (Figure 7 C,D).  
K212!
V215! I213!P214!
Active!
DEVD!
DEVD!
A! B!
 90°!
I195!
E196!
15 
 
Figure 7: Allosterically inhibited caspase-7 
(C) The L2’ loop (colored sticks) is in the ‘‘down’’ position both in the zymogen and allosterically 
inhibited (allosteric model shown, PDB ID 1SHJ) conformations. The magnitude of the L20 loop 
rearrangement is clearly visible compared to (A). Mutated residue Y211 is represented as yellow 
while resides 212–215 are colored is as in (A). (D) The hydrogen-bonding network (dashed lines) 
at the dimer interface comprises interactions between L2’ from one monomer and L2’ from the 
opposite side of the dimer (dashed lines). 
In the absence of substrate, the mature caspase-7 is in a partially active conformation 
(Figure 8 E,F). L2 is in the conformation that allows substrate binding, but L2$ is in the 
down position that is more similar to the zymogen and allosterically inhibited 
conformations. Thus, the L2$ position correlates with caspase-7 activity. 
 
Figure 8: Mature caspase-7 
(E, F) The half-active conformation observed in the mature (cleaved but substrate-free) form of 
caspase-7 (PDB ID 1K86) is colored as (A). Although the L2 loop is in a similar conformation to 
the active-site-bound structure, the L2’ loops point down toward the allosteric cavity in a 
conformation most similar to the allosteric/zymogen conformation. For additional clarity not 
possible in paper form, see Supporting Information Movie S1. 
Y211!
I213!
P214!K212!
V215!
Inactive!
C! D!
I213!
P214!
K212!
V215!
L2 loop!
F!E!
Mature!
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This canonical caspase-7 activation model suggests L2 and L2$ can only interact properly 
after cleavage by initiator caspases to generate the free loops, meaning that both of the 
caspase monomers must be cleaved to achieve a fully active caspase. Thus, both the L2 
and L2$ loops are central in caspase activation. Recently, however, hybrid dimers of one 
uncleavable and one cleavable caspase monomer suggest that cleavage of both monomers 
in not necessary for formation of one catalytically active site62,63. This implies that the 
uncleaved intersubunit linker can also adopt the conformation of either L2 or L2$ but not 
both. The L2 loop has been implicated in an allosteric network in caspase-1 in which the 
two catalytic sites are coupled through an extensive hydrogen-bond network.62 It remains 
to be seen if this allosteric coupling is present in all of the caspases and what role the L2$ 
might play in this mechanism. 
The fact that the L2$ loop is not in the correct orientation in the mature and zymogen 
conformations has been suggested to be the basis for the lack of activity in the 
zymogen39. Some mutagenesis inquiries have probed the role of L2 in caspase activity, 
and report that mutations in this region are deleterious.64,63,32 On the basis of structural 
observations, we anticipate that the L2$ loop likewise plays an important role in caspase 
function. To our knowledge, we report the first systematic study of the L2$ loop. Given 
the difficulties that have been encountered in developing active-site-directed caspase 
therapeutics, this region is particularly interesting because it is distal from the catalytic 
site, but appears to be influential for both substrate binding and catalysis. 
Analysis of the existing crystallographic structures of caspase-7 indicates that residues in 
the L2$ loop buttress the L2 loop into the proper configuration of the active-site loop 
bundle. We investigated the role of the L2$ loop by serial alanine substitution of residues 
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211–215, which form the core of the buttress. The resulting mutants were tested to 
determine the severity of these mutations on kinetics and apparent thermal stability. To 
assess the structural changes in the most severely affected mutant, we solved the crystal 
structure and compared the results with the existing caspase-7 structures. 
Results 
Role of the L2! loop in catalytic efficiency in caspase-7 
The placement of L2$ in the active conformation at the base of the active-site loop bundle 
suggests that it may be essential for substrate binding. Alanine mutants were designed to 
probe the regions of greatest interaction between L2 and L2$ (211–215) in previous 
crystal structures of caspase-7 in the active conformation (Figure 6 A).37,38,61 In caspase-
3, the residues in the region of the L2$ loop are identical to caspase-7 (Figure 9) with the 
exception of position 211 (caspase-3 position 185). Additionally, in the crystal structures 
of active caspase-3, the L2$ loop is in an identical conformation29,37,65,31,33,66 suggesting 
that the buttressing role is conserved within the executioner caspases.  
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Figure 9: Sequence alignment of the L2’ loop in related caspases 
Caspase-7 residue 213 (Ile) is conserved in size or type in not only apoptotic executioner caspases 
(caspase-6, -3, and   -7) but also apoptotic initiators (-8, -9, and -10), C. elegans CED3, the first 
discovered caspase, the inflammatory caspases (-1 and -4) and caspase-14, the epidermal-specific 
caspase. This residue is not conserved in the initiator caspase-2 or the inflammatory caspase-5. 
Given the buttressing role of the L2$ loop, alanine substitution should be a useful probe 
for the role of each residue in the formation of the active-site loop bundle as mutations of 
critical residues would have a strong impact on Km. 
Kinetics of wild-type and mutant caspase-7 variants were tested as a function of substrate 
concentration to evaluate Km and kcat (Table 1).  
 
 
CASP-1   ........LSLPTTEEFEDDAIKKAHIEK......!
CASP-5   ........ISSQSSENLEADSVCKIHEEK......!
CASP-2   ............SPGCEESDAGKEKLPKMRLPTS. !
CASP-4   ........ASSQSSENLEEDAVYKTHVEK......!
CASP-8   ............PYLEMDLSSPQTRYIPDEA....!
CASP-10  ................EQAPTSLQDSIPAEA....!
CASP-9   GSNPEPDATPFQEGLRTFDQLDAISSLPTPS....!
CED3     FLRRGWDNRDGPLFNFLGCVRPQVQQVWRKKPSQA!
CASP-6   .......QTEKLDTNITEVDAASVYTLPAGA....!
CASP-3   ...................DDMACHKIPVEA....!
CASP-7   ................NDTDANPRYKIPVEA....!
Interrogated !
Region!
213!
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Table 1: Kinetic parameters for caspase-7 alanine-substitution mutants 
Michaelis-Menten kinetic parameters measured on L2’ alanine-substitution mutants demonstrate 
that positions K212 and I213 are most affected by the alanine substitution.  
As anticipated, mutation of two of the residues, K212 and I213, had a significant effect 
on substrate binding as assessed by Km, while the Km for K212A was ∼10-fold weaker 
than wild-type caspase-7. The Km for I213A at ∼20-fold weaker than wild type is the most 
significant effect observed. I213A is the only mutation that has a significant impact, an 
∼5-fold decrease, in kcat. Mutation at Y211, P214, and Y215 had minimal impact on the 
catalytic efficiency. Catalytic efficiency (kcat/Km) of only K212A and I213A was 
significantly different from wild type, at 4- and 100-fold decreases, respectively. These 
results identify K212 and I213 as the most critical residues in the L2$ buttress. 
Alignment of the L2$ region of the caspases (Figure 9) indicates hydrophobic and size 
conservation of the 213 position, but not a strict conservation of amino acid identity. 
Caspase-1, -3, -7, and -10 use isoleucine at this position, whereas other caspases 
substitute only valine and leucine, which are nearly isosteric with isoleucine. Position 
212, which exhibited the second most significant Km effect when mutated to alanine, is 
not conserved across the caspase family. Position 212 is nearly always hydrophilic; 
 
 
Km (µM) 
 
kcat (s-1) 
 
106 x [kcat/ Km]
 
(M-1s-1) Relative Activity 
(relationship factor of mutant 
kcat/Km versus WT ) 
WT 
 
23 ± 2 
 
0.35 ± 3!10-3 
 
0.015 1.0 
Y211A 
 
18 ± 10 
 
0.39 ± 3!10-3 
 
0.021 1.4 
K212A 
 
210 ± 20 
 
0.93 ± 4!10-2 
 
0.004 0.26 
I213A 
 
480 ± 50 
 
0.07 ± 5!10-3 
 
1.5!10-4 0.01 
P214A 
 
8 ± 1 
 
0.10 ± 4!10-3 
 
0.012 0.8 
Y215A 
 
26 ± 8 
 
0.70 ± 2!10-2 
 
0.026 1.7 
!
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however, sizes vary from small (serine) to long (lysine) or bulky (histidine and tyrosine). 
In the active conformation of wild-type caspase-7, the exposed aliphatic portion of the 
lysine side chain is packed against the aliphatic portion of E196 (Figure 6 B). 
Interestingly, these residues are not strictly conserved in the third executioner caspase, 
caspase-6. Conservation of this region is weak compared with the region flanking the 
catalytic cysteine C186 (residues 178–188). 
L2! mutations affect protein stability 
Alanine mutations have been reported to generate cavities in protein cores67. Because 
alanine mutants have the possibility of introducing a destabilizing cavity, we probed the 
stability of the protein in the mature (substrate unbound) form using thermal denaturation 
monitored by circular dichroism (Figure 11). Inspection of caspase-7 structures suggests 
that the only important interactions that form in the substrate-bound conformation but not 
in the mature or zymogen form are between L2 from one monomer and L2$ from the 
opposite monomer. Thus, interrogation of the stability of wild-type and mutant caspases 
in the active conformation [with substrate-like inhibitor, the caspase-binding peptide 
aspartate–glutamate–valine–aspartate (DEVD) bound] was also relevant. 
The serial alanine mutations appear to have no discernable effect on the overall fold of 
the protein in either the inhibitor-bound versus unbound states, as the measured spectra at 
25°C were unaffected by mutation. The melting temperature (Tm) of all mutants in the 
unbound form was similar to wild type at ∼60°C, except for the P214A mutation which 
had a Tm of 46°C (Figure 11).  
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Figure 10: Tm Curve Data for WT and alanine scanning mutants  
Raw circular dichroism data monitored at 222 nm during a thermal denaturation of proteins. Tm 
calculated by fitting a Boltzmann sigmoidal curve to data collected.  Data for V215A, 
K212A+DEVD-CHO and WT+DEVD-CHO were collected in triplicate, not shown. All other data 
were duplicate measurements made independently on different preparations on separate days. 
 
 
Figure 11: Melting temperatures and cavities generated in caspase-7 variants. 
Melting temperatures (Tm) were measured by thermal denaturation monitoring the change in CD 
signal at 222 nm in the presence (white bars) and absence (black bars) of the active-site inhibitor 
peptide DEVD-CHO. Measurements were made at least in duplicate with independently prepared 
samples on separate days. Error bars represent standard deviation between replicates measured on 
separate protein samples on different days. 
We had hoped to also measure thermodynamic stabilities of the caspase-7 mutants; 
unfortunately, unfolding of wild type and all of the mutant caspase-7 variants was 
irreversible and precluded accurate assessment of %Gunfolding. We calculated the predicted 
volume changes each mutation could contribute to the overall structure (Figure 12) of 
caspase-7 in the active conformation assuming there were no other structural changes in 
the protein, either backbone or side chain position. From these figures, we were able to 
assess the potential volume of each deletion and what role it might play in the stability of 
M
el
tin
g 
Te
m
pe
ra
tu
re
 (°
C
) 
25 
each protein. The Matthews group has systematically assessed the effect of cavity-
forming mutations in the core of T4 lysozyme. In one study of 44 large amino acid to 
alanine substitutions, cavities between 17 and 123 Å3 were observed 
crystallographically.67 These cavities correlated with decreases in stability (%%G) of 0.9–
5.0 kcal/mol. Several cavities were observed in the range of 25 Å3 that had %%G ranging 
from &3.2 to &2.7 kcal/mol. In T4 lysozyme, a 1.9 kcal/mol change in %%G corresponds 
to approximately a 5° decrease in Tm.68 Thus, the 14° decrease in Tm of unbound P214A 
could reflect a %%G of greater than 4 kcal/mol. 
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Figure 12: Predicted volumes of cavities in models of mutant proteins 
Volumes of cavities in models of mutant proteins generated computationally in PyMol were 
assessed with Pocketfinder. The deleted volumes are shown as colored pillows to illustrate the 
chemical environment and residues forming the generated cavity. Change in the Tm of caspase- 7 
dimers in the presence of active-site-binding peptides (DEVD-CHO) relative to ligand free is also 
listed. 
Interestingly, the Tm difference between mature and active-site-bound forms was 
pronounced, with an average 18.7°C increase in Tm of the active-site-bound form over the 
unbound form. The single observed structural difference between these two forms is that 
the inactive, unbound form is able to sample both the up conformation of L2$ and the 
inactive down conformation of L2$. When substrate is bound, L2$ is locked in the active 
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up conformation. Thus, when the protein adopts the up, bound form, it appears to be 
significantly stabilized by the interactions between L2$ and L2 from opposite monomers 
and by interactions with substrate. 
I213A has a smaller than average %Tm of 7°C between the forms (Figure 11), indicating 
that an energetic penalty must be paid to adopt this conformation because the active form 
is less stable to thermal denaturation. The dramatically destabilized P214A mutant, on the 
other hand, showed a %Tm of 31°C between bound and unbound forms. Although the 
identity of 214 seems to be more influential in the inactive form, in the active form, the 
stability is comparable to the wild-type enzyme. This can be explained by structural 
examination of the active form where P214 seems to have a more limited role in 
buttressing than I213 (Figure 6, Figure 7, Figure 8). In the active conformation, L2–L2$ 
physical interactions tend to dominate over any geometric constraints imposed by P214. 
The substitution of P214A has a negligible effect on active (bound) enzyme stability; 
however, in the inactive form, the hydrogen-bonding network present between L2$ and 
L2$ from the opposite monomer would likely be disrupted as the geometric constraints 
imposed by the proline at position 214 are removed by the alanine substitution. This 
substitution, however, does not inhibit dimerization of the protein, as measured by size 
exclusion chromatography (Figure 13).  Both WT and P214A proteins ran at an 
apparently smaller size than expected for the dimer of caspase-7 (60 kD). We noted a 
decrease in apparent size of P214A relative to WT, however we postulate that the more 
flexible nature of the loops decreases the proteins apparent interaction with the gel, 
causing the smaller than expected (60 kD) size.  
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Figure 13: Size exclusion chromatography 
Size exclusion chromatography of caspase-7 WT and P214A with and without inhibitor bound. In 
the presence of inhibitor, P214A’s calculated size is similar to WT with inhibitor. The difference in 
size of apo P214A versus WT is not appreciable.  
 
Analysis of caspase-7 by analytical ultracentrifugation 
We postulated that the decreased stability of caspase-7 P214A due to the more flexible 
L2’ loop would have an appreciable effect the dimerization constant. Clark and 
colleagues have reported an estimation of the dimerization constant for caspase-3 to be 
below 50 nM69, so we imagined that caspase-7 P214A would be sufficiently destabilized 
in the apo state to monitor this by analytical ultracentrifugation. P214A in the absence of 
Protein 
RT 
(mL) 
SEC 
Observed 
MW (KDa) 
15.68  
15.26  
15.28  
15.33  
54  
55 
45 
53 WT + DEVD 
WT 
P214A + 
DEVD 
P214A 
Standards 
Expected 
MW (KDa) 
60 
61 
60 
61 
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covalent catalytic inhibitor was studied by analytical ultracentrifugation in equilibrium 
mode to determine dimerization constant. The estimated molecular weight from AUC 
was determined to be 53 kD and a single species. Fitting monomer-dimer equilibrium 
was unsuccessful as at experimental conditions of 10-20 µM, no monomer was detected. 
These data suggest that the Kd of dimerization is significantly below 10 µM and does not 
appear to be changed from WT caspase-7. Thus, further experiments to determine 
experimental Kd of WT by AUC was not attempted due to equipment restraints. In 
hindsight, the ability to collect accurate kinetics on protein at 100 nM should have 
suggested that the P214A’s dimerization constant was below 100 nM.  
 
Figure 14: Equilibrium AUC analysis of P214A apo 
Single species fitting of equilibrium data based on two concentrations and three rotor speeds. Fitted 
line (blue dots) overlays data (black dots) very well, with statistical residuals (bottom) maintaining 
sufficient randomness.  
Additional experiments undertaken to lower experimental concentrations and thereby 
increase monomer population in solution were unsuccessful, because the limit of 
detection of the instrument was reached. At concentrations below 5 µM protein, data 
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collected were too noisy to process, making measurements in the concentration regime of 
caspase dimerization impossible69. Thus we can only conclude that the dissociation 
constant is well below 10 µM. Furthermore, because caspase-7 and the P214A mutant 
show activity at 100 nM protein concentrations, and dimerization is known to be essential 
for activity, we can further conclude the dissociation constant is less than 100 nM in the 
presence of substrate.  
 
Figure 15: MW calculation for P214A apo AUC data 
Fitting parameters and results from single species fitting of equilibrium data based on two 
concentrations and three rotor speeds. A molecular weight of 53kD was fit with 2084 points, with 
an RMSD from fit of 0.011.   
Thus, we can conclude that substrate binding and the concomitant stabilization of 
interactions observed between the L2 and L2$ loops are the most critical factors in 
significant stabilization of the active-bound conformation. Indeed, substrate binding 
appears to be so influential in locking L2$ securely into the up conformation that it can 
overcome significant thermodynamic destabilization in the unbound state. Because 
P214A had negligible effect on both the stability of the substrate bound form and the 
kinetics of the enzyme, we focused our investigation on the structural differences caused 
by the I213A mutation to further understand the structural role of the L2$ loop in 
substrate binding and catalysis. 
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P214A Mutation does not affect DICA binding 
In the crystal structure of caspase-7 bound to allosteric inhibitors (1SHJ and 1SHL), loop 
L2’ is positioned over the allosteric site. In those structures, residues I213 and Y211 form 
a hydrogen bonding network that potentially stabilizes the resting state or ‘half active’ 
conformation of caspase-7. Stability measurements (Figure 11) suggest that in this 
hydrogen bonding network is disrupted by the mutation of P214 to alanine, likely due to 
the additional degrees of freedom afforded by the alanine. Proline imposes geometric 
restraints not found in alanine, and the subsequent destabilization of the loops could 
account for the 13.8° difference in Tm. To investigate whether this difference and loop 
flexibility would affect DICA binding and removal, caspase-7 WT and P214A were both 
incubated with DICA. Both proteins responded similarly to DICA inhibition, and were 
found to be fully inhibited within 1 hour. Reductive removal of DICA from the allosteric 
cavity using DTT at various concentrations (100 µM and below in a two fold dilution 
series) indicated no statistically significant difference between the wild type enzyme and 
the P214A variant. (Figure 16) This suggests the loop L2’ makes additional interactions 
with DICA that stabilize L2’ in the down conformation, occluding the accessibility of 
reductant to C290 in both WT and P214A. Interestingly, it was found that high 
concentrations of TCEP have an inhibitory effect on both WT and P214A caspase-7 at 
concentrations above 50 µM. This same effect was not observed with the use of DTT.  
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Figure 16: Percent recovery of activity as a function of DTT concentration 
Caspase-7 WT and P214A do not show statistically significant differences when inhibited with 
allosteric disulfide linked DICA, followed by treatment with DTT reductant. Activity returns as a 
function of reductant concentrations to both WT and P214A.  
Crystallographic studies of I213A in the presence of active-site inhibitor 
Crystals of caspase-7 I213A with DEVD covalently bound in the active site to lock the 
protein in to the active conformation were grown in a variation on known conditions,61 
and the structure was solved at 2.6 Å (Table 2). To avoid model bias during structure 
determination, we omitted all of the active-site loops from the molecular replacement 
search model and thus calculated an omit map that is unbiased in the loop region as our 
initial map (Figure 17 A,B). Compared to an active caspase-7 structure that crystallized 
in the same form (1F1J37), the RMSD of all atoms was found to be 0.191 Å, further 
supporting the observation that the I213A mutation had no effect on the overall fold of 
the protein. The substrate-binding grooves and active-site inhibitor conformations in our 
structure were virtually unchanged from wild-type caspase-7. 
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Diffraction Data 
  
 
Wavelength (Å) 
 
1.54 
 
Resolution Range  (Å) 
 
50-2.61 (2.70-2.61) 
 
Measured reflections  
 
26499 
 
Unique reflections 
 
10599 
 
Completeness (%) 
 
97.8 (92.0) 
 
Redundancy 
 
2.5 (2.5) 
 
<I/!I> 
 
22.5 (1.99) 
 
Space Group 
 
P3221 
 
a = b (Å) 
 
89.4 
 
c (Å) 
 
186.1 
 
# = " (°) 
 
90 
 
' (°) 
 
120 
 Rsym  8.3 (69.4) 
    Refinement Statistics 
  
 
Atoms  
 
3919 
 
Water molecules 
 
119 
 
Rwork (%) 
 
19.9 
 
Rfree (%) 
 
25.1 
 
RMSD bond length (Å) 
 
0.019 
 
RMSD bond angle (°) 
 
1.876 
 
Average B-factor (Å) 
 
51.82 
 
Table 2: Statistics for the x-ray crystal structure of caspase-7 I213A 
Data in parenthesis are for the highest resolution bin  
 
The greatest difference between the wild-type and the I213A structure was in the Y211 
region (Figure 17 A–C). Y211 is unresolved in most caspase-7 structures of the active 
form, and only recently has been observed in structures (PDB ID 2QLF and 2QLJ) of 
active caspase-7 bound to peptide inhibitors with aldehyde warheads61.  
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Figure 17: Crystallographic evidence of compensatory mechanism that facilitates  
active-site-binding in caspase-7 I213A. 
(A) Caspase-7 I213A structure with buttress region highlighted in inset. (B) 2Fo-Fc density (blue 
mesh) from the initial omit map (residues 211–215 omitted from the phase calculation) and final 
refined model of I213A (yellow sticks) shown in same orientation as (A). (C) is as (B) but rotated 
90° for clarity. The unbiased omit map clearly indicates the down position for Y211. (D) Wild-type 
caspase-7 (green sticks) is superimposed with the final I213A model, demonstrating that the 
conformation of Y211 fills a structural void when the I213 side-chain is deleted. (E) The 
environment (gray spheres) into which Y211 (yellow spheres) inserts is hydrophilic in nature to 
accommodate the hydoxyl moiety. (F) Residues forming the cavity into which Y211 insert are in a 
nearly identical conformation in wild-type caspase-7 (green sticks) and I213A (yellow sticks). 
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In both these structures, Y211 is solvent exposed (Figure 17 D,F). In our structure 
(yellow), Y211 exhibits a radically different conformation, burying itself into a newly 
formed surface cavity. This burial appears to be a compensatory mechanism for the 
I213A cavity-forming mutation (Figure 17 D,E). This position of the tyrosine fills a void 
in the region, where I213 is found in the wild-type structure. In the wild-type 
conformation, Y211 burial is sterically occluded by I213 (Figure 17 E).  
This structural observation helps to explain the diminished kcat, in the context of residual 
catalytic activity in the I213A mutant. Given that the apparent thermal stability of I213A 
in the active-site-bound form is lower than any of the other mutants, and the lack of any 
other structural changes in this mutant crystal structure, we can conclude that the cavity 
formed by deletion of the I213 side-chain is so unfavorable as to prevent proper 
formation of the loop bundle without some compensatory reorganization. The 
compensatory conformation we observe allows the formation of a catalytically competent 
enzyme but not without an energetic penalty. 
Discussion 
Based on the work presented here, two main points emerge. First, binding of substrate 
stabilizes caspase-7 via a structurally validated mechanism. Second, the core of the L2$ 
loop is residue I213 and this buttressing region is an essential component of active 
caspase-7. If the core of the L2$ loop is perturbed, then the L2$ loop does not properly 
hold L2 in place, the substrate-binding loop bundle is therefore destabilized and Km of the 
resulting mutants are increased. 
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Caspase-7 is a constitutive dimer and is not believed to exist in the monomeric state to a 
significant degree70. In contrast, the initiator caspase-9 is predominantly an inactive 
monomer before activation by the apoptosome. Binding of active-site inhibitors drives 
caspase-9 to the dimeric state70. Thus, it is plausible that other caspases would likewise 
be stabilized by binding of active-site inhibitors. To our knowledge, no other group has 
shown and quantified the dramatic stabilization of the active-site bound form of caspase-
7 compared with the unliganded state. Prior computational analysis of the stability of the 
active versus unbound conformation mirrors our experimental results, indicating that the 
L2$ up or active conformation of caspase-7 was significantly more stable than the L2$ 
down conformation71.  
The roles of individual residues in the L2$ loop obviously change depending on the state 
(active-site-bound or unbound) of the protein. The structures of the mature unbound form 
of caspase-7 (Figure 8 E,F) when compared with the active (Figure 6 A,B) and 
allosterically inhibited (Figure 7 C,D) forms suggest an ensemble of states that are in 
dynamic equilibrium with one another. Two of our mutants, I213A and P214A, support 
the idea that the L2$ loop is critical for stabilizing the active-site-bound conformation. 
I213A caspase-7 has the same apparent thermal stability in the unbound form as does 
wild type. This indicates that the equilibrium constant for unfolding of the unbound form 
is likewise unchanged from wild type. On the other hand, the Tm of the active-site-bound 
form is slightly lowered, possibly suggesting that an energetic penalty must be paid to 
achieve this conformation. The crystal structure of I213A indicates that the decrease in 
stability is due to the cost of hydrophilic burial when Y211 intercalates into the I213A 
cavity to properly buttress the loop bundle (video of interaction can be accessed from 
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Protein Science Supplementary resource website, at: 
http://onlinelibrary.wiley.com/store/10.1002/pro.151/asset/supinfo/PRO_15_sm_suppmo
v2.mov?v=1&s=479f68a02900b7636d650589416d8e9a5bcb35ea). We anticipate that in 
the unbound form of I213A, L2$ is free to sample the down conformation, whereas in our 
structure, binding at the active site locks L2$ into the active, up, conformation. If caspase-
7 natively sampled the active, up, conformation to a significant degree when the active 
site was empty, this up conformation would lower the stability of the unbound form of 
the enzyme. Because the I213A unbound apparent thermal stability is unchanged, it 
seems that the up conformation of the L2$ loop does not contribute significantly to the 
conformational equilibrium ensemble of the unbound form. Thus, proper ordering of the 
L2$ loop as a buttress for L2 is so essential for active-site-binding that the enzyme will 
pay an energetic penalty to maintain the active state. 
The P214A mutant displays the opposite effect on stability. P214A is destabilized in the 
unbound state by a significant margin (14°C relative to wild type). Interestingly, when it 
is locked into the active conformation by active-site binding, the complex is as stable as 
the wild-type enzyme. This indicates the absence of energetic penalties like those 
observed for I213A and further suggests that the conformation of this mutant when the 
active site is bound is identical to wild type. The interactions of L2 with L2$ are the only 
additional interactions within the caspase protein itself that are observed on going from 
mature unbound caspase-7 to active-site-bound caspase-7. The fact that a dramatic 
destabilization of the unbound form of P214A can be overcome by active-site binding 
indicates that these L2/L2’ interactions are responsible for the jump in apparent thermal 
stability observed in all versions of caspase-7. Structural analysis suggests that the L2$-
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loop up conformation should be more stable as it has better burial of exposed 
hydrophobic residues. Likely, an entropic penalty for ordering of mobile loops prevents 
this conformation in the absence of active-site binding. Moreover, the conformational 
equilibrium in the bound state has essentially no component of the unbound state, which 
would lead to destabilization of both the unliganded and liganded states. 
One of the looming controversies in understanding caspase structure and activity is the 
structural state of the mature (cleaved) protein in the absence of active-site ligand. There 
is but one existing crystal structure of unliganded, mature caspase-739. In this structure, 
the active-site loops do not adopt the substrate-bound conformation (L2 and L2$ up), but 
are in a half-active conformation with L2 up but L2$ down. In contrast, mature caspase-3 
has been reported to exist in the liganded conformation (L2 and L2$ up) with an empty 
active site, crystallized in the presence of what the authors term a noncatalytic site 
inhibitor, which is not observed in the crystal structure.31 The fact that a mutation in L2$ 
exists, namely P214A, that dramatically affects the stability of the unliganded state but 
not the liganded state suggests that without ligand, the L2$ loop is in a conformation that 
differs from the active state. If the unliganded enzyme “rested” in the active (L2$ up) 
conformation, as suggested by the mature caspase-3 structure31, then this mutation should 
have the same energetic effect on the active-site liganded form as on the unbound form. 
As this is not the case, our analysis supports the notion that structural rearrangements that 
are observed in the existing crystal structures of caspase-737,39,41,42,61 are the biologically 
relevant conformations. 
In the context of the other mutagenesis data, the Y211A mutation indicates that 
interactions between the backbones of the L2$ loops covering the allosteric pocket are the 
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major energetic contributors to the allosterically inhibited/zymogen complex. In the 
active conformation, the interactions between the L2 loop from one half of the dimer and 
the L2$ loop from the other half of the dimer have a tremendous stabilizing effect on 
caspase-7, as the addition of active-site inhibitor increases the apparent thermal stability 
of the complex by 12–19°C. Thus, the L2$ loop appears to play important roles in both 
substrate binding and maintaining caspase-7 in an inactive yet still dimeric conformation. 
We report a large perturbation (10- to 20-fold) in the Km of two caspase-7 variants 
(K212A, I213A) with alanine substitutions in the L2$ loop. Although the L2$ loop is 
further away in both amino acid sequence and in space than the L2 loop is from the 
catalytic residues, our reported mutations had as a great an effect on substrate binding 
and catalytic efficiency as did mutations in the L2 loop. Clark and coworkers32 mutated 
caspases-3 residues 167, 169, 173, and 203 (homologous residues in caspase-7 are 190, 
192, 196, and 229) to alanine. The residue with the most significantly impaired substrate-
binding properties was D169A, in which Km was increased 35-fold relative to wild type. 
It is significant that our mutants had the same magnitude effect on substrate binding as 
mutations in the L2 loop because structurally the two loops also appear to act in concert. 
Another region of the caspase substrate-binding loop bundle that has been widely 
discussed as being critical for caspase activity is the DDD “safety catch” in the L2$ loop 
in caspase-3. This “safety catch” comprises residues 179–181 (caspase-7 residues 205–
207) and was found to be critical for activation of procaspase-364. The DDD “safety 
catch” region is further from the active site, has not been observed in crystal structures, 
and is unlikely to make physical buttressing interactions like those we observe in the L2$ 
buttressing region. Although the DDD region is essential for proper cleavage and 
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activation of caspase-3, the L2$ loop may be a more tractable target for new methods of 
caspase regulation. 
Before this work, the L2$ loop was implicated in both the active and 
zymogen/allosterically inhibited conformations. In the active state, L2$ is part of the 
substrate-binding loop bundle. In the zymogen/allosterically inhibited state, L2$ forms a 
lid occluding the allosteric cavity. Interconversion between the active and inactive 
conformations had been observed, but the energetic contributions of L2$ to these two 
conformations were unclear. Our work demonstrates that residues 212 and 213 are 
critical for proper functioning of the L2$ loop, particularly in binding substrate. We have 
shown that I213, in particular, serves as a critical buttress for holding the L2 loop (which 
is connected to the catalytic cysteine) in place and thus stabilizing the active form of the 
enzyme. If L2$ is not in the up conformation, the entire loop bundle is destabilized. This 
buttressing region is present in the homologous conformation in structures of the other 
active caspases indicating that the results we report may be relevant to the entire caspase 
family. 
This understanding of the role of the L2$ loop as critical for formation of the active-site 
loop bundle also provides clues toward new mechanisms for pharmacological control of 
caspases. Molecules that bind overlapping with the buttressing region occupied by I213 
and neighbors should work as allosteric inhibitors of caspase function. Similarly, 
molecules that bind behind the L2/L2$ interacting region [which is on the back side of 
caspase-7 in (Figure 6 (A), Figure 7 (C), Figure 8 (E)] should stabilize the active 
conformation and serve as heterologous caspase activators, which are a long-sought 
entity. Given recent evidence that the uncleaved form of caspase-7 can support catalysis 
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in a hemicleaved heterodimer,62,63 this mechanism of activation might even prove more 
relevant for activation of procaspases. 
Materials and Methods 
Caspase-7 mutant generation, expression, and purification 
Wild-type and mutant versions of caspase-7 were expressed from a two plasmid 
expression system39. The constructs encoding residues 50–198 comprise the large 
subunits and were contained in the pRSET(AmpR) plasmid. The constructs encoding 
residues 199–303 and one codon for Q plus a six-histidine tag are contained in the 
plasmid pBB75 (KanR) plasmid72. Mutants in the small subunit were generated using 
QuikChange (Stratagene) site-directed mutagenesis. The recombinant large and small 
subunits were coexpressed in E. coli in 2( YT media grown for 18 h after induction with 
1 mM Isopropyl "-d-1-thiogalactopyranoside at an OD600 of 0.6. Wild-type and mutant 
caspase-7 variants were purified using Ni-affinity liquid chromatography (HiTrap 
Chelating HP, GE). After binding of protein to the affinity column, the protein was eluted 
with a step gradient from 50 to 250 mM imidazole. Protein was diluted to 50 mM NaCl 
and then purified using a Macro-Prep High Q ion exchange column (Bio-Scale Mini 5 
mL, Bio-Rad) with a linear gradient from 50 to 500 mM NaCl in 20 mM Tris buffer pH 
8.0, with 2 mM DTT. Protein eluted in 120 mM NaCl and 20 mM Tris pH 8.0 was 
assessed for purity by SDS-PAGE to be 98%+ pure and stored in elution buffer at &80°C. 
Caspase-7 I213A crystallization and X-ray data collection 
To prepare I213A crystals, 29 µM I213A protein in a buffer containing 120 mM NaCl 
and 20 mM Tris pH 8.0 was incubated at room temperature with a 3:1 molar ratio of 
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DEVD-CHO (asp–glu–val–glu-aldehyde, BioMol) to protein for 3 h. Optimal protein 
labeling occurred with the addition of enzyme to the small volume of DMSO-solvated 
inhibitor. The extent of enzyme labeling was confirmed by activity determination. Protein 
was then concentrated using Millipore Ultrafree 5K NMWL membrane concentrators 
(Millipore) to 11 mg/mL as assessed by absorbance at 280 nm. Crystal tray setup was 
conducted on ice with cooled buffers. Crystals were grown in 2 µL hanging drops with 
mother liquor consisting of 14% polyethylene glycol 3350, 300 mM diammonium 
hydrogen citrate at pH 5.6, 10 mM guanidine hydrochloride, and 10 mM DTT in a 1:1 
ratio of protein mother liquor. Crystals grew to a maximum of 200 µm in 48 h at 4°C. 
Crystals were cryoprotected in 14% polyethylene glycol 3350, 300 mM diammonium 
hydrogen citrate at pH 5.6, 21% glycerol, and 10 mM DTT with a 60 second incubation, 
then frozen by rapid immersion in liquid N2. Data were collected on an R-axis IV++ 
detector using a Rigaku X-ray generator and showed diffraction data to 2.4 Å. Indexing, 
integration, and scaling were carried out on HKL200073. Low I/) in the high-resolution 
shells forced the dataset to be restricted to 2.61Å. Only 47° of data were collected, 
resulting in low overall data redundancy, because of a power outage leading to the loss of 
the crystal. 
Structural determination 
Phase information was obtained by molecular replacement using 1F1J as the search 
model with residues 194–196/494–496 and 212–213/512–513 omitted during searches 
with CCP4 AMoRe74. Tyrosine at position 211/511 was not present in the parent model. 
Removed residues were rebuilt into unambiguous density using O,75 then refined with 
three rounds of Refmac restrained refinement using medium strength NCS averaging 
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restraints. Waters were inserted with multiple rounds of ARP/Warp then checked for 
stereochemical viability manually. The final refined model contains residues 58–196, 
211–303 for chain A and 57–196, 211–304 for chain B. The inhibitor is modeled as 
chains C and D, with residue numbers 701–705 and 801–805, respectively, and 119 
ordered waters as chain W. 
Caspase activity assays 
Enzyme concentrations were determined by active site titration with suicide substrate 
DEVD-Fluoromethylketone (BioMol) in caspase activity buffer containing 100 mM 
Hepes pH 7.0, 10% polyethylene glycol 400, 0.1% CHAPS (3-[(3-
cholamidopropyl)dimethylammonio]-1-propanesulfonate), 5 mM "-mercaptoethanol, and 
5 mM CaCl2 against flourogenic substrate, DEVD-AMC (7-Amino-4-methylcoumarin), 
Ex365/Em495 (BioMol). Active site titration setups were incubated over a period of 4 h 
in 120 mM NaCl, 20 mM Tris pH 8.0 at nanomolar concentrations. Optimal labeling was 
observed when protein was added to DEVD-FMK solvated in DMSO in 96-well V-
bottom plates, sealed with tape, and incubated at room temperature. Ninety microliters of 
aliquots were transferred to black-well plates in duplicate and assayed with 50-fold molar 
excess of substrate. For kinetic measurements, 50 nM protein (500 nM in the case of 
K212A, I213A) was assayed over 0–180 µM DEVD-AMC (0–500 µM for K212A, 
I213A) over a course of 7 min. Assays were performed at 37°C in 100 µL volumes in 
microplate format using a Molecular Devices Spectramax M5 spectrophotometer. Initial 
velocities versus substrate concentration were fit to a rectangular hyperbola using GraFit 
software (Erithacus Software) to determine kinetic parameters Kmand kcat. 
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DICA inhibition and reduction assays 
DICA removal assays were conducted on both WT and P214A proteins buffer exchanged 
into 10mM sodium phosphate buffer pH 7.5.  Proteins were then incubated for 1h in 10X 
molar excess of DICA, followed by a buffer exchange to remove excess DICA. Proteins 
were then diluted to 110 nM as assayed by A280, and incubated in a 2 fold dilution series 
of DTT (starting at 100 µM) for 30 minutes and assayed for activity against a control 
under identical conditions without DICA.  
Sizing column analysis  
The oligomeric state of the caspase-7 WT and P214A in the presence and absence of 
DEVD-CHO was determined by running protein samples on a Superdex 200 10/300 GL 
(GE Healthcare) gel-filtration column. Both inhibited and apo proteins were then buffer 
exchanged into 20mM Tris, pH 8.0, 100mM NaCl using Millipore Ultrafree 5K NMWL 
membrane concentrators (Millipore), and 200 µl of protein (1.2 – 2 mg/ml) was loaded 
onto the column. Protein was eluted with 20mM Tris, pH 8.0, 100mM NaCl. The identity 
of the peak fractions and the loaded protein sample were analyzed by SDS-PAGE. Four 
different molecular weight standards (Albumin, Chymotrypsinogen A, Ribonuclease A, 
Ovalbumin) from the gel-filtration calibration kit (GE Healthcare) were run in the same 
conditions and a standard plot was generated to calculate molecular weights of caspase-7 
WT and P214A in presence and absence of inhibitor. 
Analytical ultracentrifugation  
Analytical ultracentrifugation of caspase-7 P214A in equilibrium experimental mode 
were run on Beckman Optima XL-1 analytical ultracentrifuge using an An-60 Ti rotor 
with a 6 cell equilibrium cuvette (Spin Analytical). Proteins were buffer exchanged into 
45 
10mM sodium phosphate buffer pH 7.5 and concentrated using Millipore Ultrafree 5K 
NMWL membrane concentrators (Millipore). Protein concentrations of 15 µM, 10 µM 
and 1 µM were run to equilibrium at 14,000, 18,000 and 21,000 RPM for 14 hours each 
at 20°C and monitored by UV at 280 nM in columns heights of ~2.8mm. Density of the 
buffer and the specific volume of the protein were calculated with ULTRASCAN II76, 
while data for the 15 µM and 10 µM were analyzed by SEDFIT77 and SEDPHAT77,78 
using the continuous distribution model. Additional analytical ultracentrifugation data 
analysis support was graciously supplied by Dr. Jeffery Lary of the University of 
Connecticut.  
Thermal stability determination 
Thermal denaturation of wild-type or caspase-7 variants was monitored by loss of 
circular dichroism signal at 222 nm on a J-715 circular dichroism spectrometer (Jasco) 
with a PTC-348WI Peltier controller. Inhibited protein was prepared by 4-h incubation 
with 3M equivalents of DEVD-CHO (asp–glu–val–glu-aldehyde, BioMol) at a 
concentration of 6–12 µM in 120 mM NaCl, 20 mM Tris pH 8.0. Both inhibited and apo 
proteins were then buffer exchanged into 10 mM phosphate buffer, pH 7.4 using 
Millipore Ultrafree 5K NMWL membrane concentrators (Millipore) for repeated 
concentration and dilution until NaCl concentration was below 1 nM and protein 
concentration of ∼12 µM as assessed by absorbance at 280 nm. Data were collected in 
duplicate on separate days and fit using Origin Software (OriginLab) using sigmoid fit. 
Assessment of generated cavity volumes 
Models of the alanine-mutant caspase-7 variants were generated in PyMol79 and analyzed 
with Pocketfinder80 to predict the volume of pockets created by alanine mutations. 
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CHAPTER III 
A DESIGNED REDOX-CONTROLLED CASPASE 
Abstract 
Caspases are a powerful class of cysteine proteases. Introduction of activated caspases in 
healthy or cancerous cells results in induction of apoptotic cell death. We have designed 
and characterized a version of caspase-7 that can be inactivated under oxidizing 
conditions like those found extracellularly, then reactivated under reducing, intracellular 
conditions. This version of caspase-7 is allosterically inactivated when two of the 
substrate-binding loops are locked together via an engineered disulfide. When this 
disulfide is reduced, the protein regains full function. The inactive loop-locked version of 
caspase-7 can be readily observed by immunoblotting and by mass spectrometry. The 
reduced and reactivated form of the enzyme observed crystallographically is the first 
caspase-7 structure in which the substrate-binding groove is properly ordered even in the 
absence of an active-site ligand. In the reactivated structure, the catalytic dyad cysteine-
histidine are positioned 3.5 Å apart in an orientation that is capable of supporting 
catalysis. This redox-controlled version of caspase-7 is particularly well-suited for 
targeted cell death in concert with redox-triggered delivery vehicles. 
Introduction 
The loops that form the caspase substrate-binding groove are extraordinarily mobile and 
controlling their conformation controls caspase function. Amongst caspases, the most 
thorough molecular descriptions of activation, regulation and inhibition have been in 
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caspase-7. In the procaspase-7 zymogen, the active-site loops are disordered and 
incompatible with substrate binding39. Upon activation the active-site loops are partially 
ordered, but the L2’ loop remains in an inactive, down conformation (Figure 18 A). From 
this state caspase-7 is competent to bind substrate or to bind allosteric inhibitors, 
mutually exclusively. When substrate binds, L2’ moves to an up conformation, forming a 
foundation or buttress beneath the L2 loops37,39,41,61. When caspase-7 binds allosteric 
inhibitors in a cavity at the dimer interface, the L2’ loops are held in the down 
conformation and the enzyme is inactive81,82. Thus controlling caspase-7 loop 
conformations is an effective way to modulate activity. 
Caspases are found only intracellularly and must function inside the cell to activate 
apoptosis.  Caspases make use of a cysteine-histidine active-site dyad for proteolysis. The 
catalytic cysteine nucleophile must be maintained in a reduced state to function. 
Glutathione is the most prevalent cellular redox component. Intracellular glutathione 
concentrations in healthy cells range from 1-5 mM, with cancerous cells showing 
concentrations up to 7-fold higher,83 whereas extracellular concentrations are 1-4 µM84. 
Thus differences in redox environment provide an intriguing means of differentially 
controlling intracellular and extracellular activity.  
Caspases are exquisitely useful cellular players. Once activated they singlehandedly 
induce the demise of a cell. There is a great deal of interest in small-molecule activation 
of caspases, however this has been challenging to achieve85-87. Another option for 
selective killing of cells therapeutically is the use of pre-activated caspases. Injecting 
activated caspases, or any activated protease, into circulation is likely to produce many 
unwanted and deleterious effects. In order to avoid these complications while still taking 
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advantage of the cell-killing properties of activated caspases, we aim to engineer a 
version of the executioner caspase-7 that can be held in an inactive conformation in the 
oxidizing extracellular environment, but regains full activity in reducing intracellular 
conditions. Targeted delivery of this type of engineered caspase could potentially provide 
a safe and effective mechanism of selectively killing unwanted cell types. 
Results 
Rational design of a redox activatable caspase-7.   
The aim of this work is to control the conformation of the L2’ loops in order to 
allosterically regulate caspase-7 function. In the crystal structure of caspase-7 bound to 
allosteric inhibitors FICA or DICA, caspase-7 attains a conformation that is distinct from 
the mature or substrate-bound forms. We have previously shown that caspase-7 likewise 
exists in two distinct conformations in solution88, a bound active state and an unbound 
inactive state.  In the inactive state with no substrate present, the L2’ loops rest over the 
allosteric cavity and do not contribute to the formation of the active-site loop bundle.  
The L2’ loops from the opposite sides of the dimer form an anti-parallel structure with a 
nearly 90° crossing angle. The residues with the closest approach are the two R210 
residues, with a C#-C# distance of 5.5Å (Figure 18 A).  
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Figure 18: Design of a reductant activatable caspase-7 
The allosterically inactivated caspase-7 dimer consists of two chains (A chain, green; B chain, 
blue). (A) An introduced disulfide between R210C residues on the two chains (white and yellow 
spheres) is designed to lock the protein into the inactive conformation by keeping the L2’ loops in 
the down conformation. Formation of this disulfide would result in a covalently crosslinked small-
subunit homodimeric species. (B) Pairs of native cysteines (C100 and C246, blue and yellow 
sticks) are computationally predicted to form disulfides on each side of the dimer. These disulfides 
would drive formation of a large subunit-small subunit crosslinked species. 
We modeled pairwise mutations to cysteine for all residues in the L2’ loops then used the 
MODIP89 server to score the probability of forming various disulfides. MODIP scored an 
R210C-R210C disulfide in the C category on a scale of A (most favorable) to F (least 
favorable). This intermediate score may be related to the fact that all C# positions are 
fixed during MODIP modeling. The L2’ loop is necessarily flexible, as it undergoes 
significant rearrangement during the caspase lifecycle, thus a score of C may still indicate 
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a favorable interaction. In contrast, a second potential native disulfide, which we 
subsequently observed crystallographically (Figure 19), was scored as an A.  
 
 
Figure 19: Observation of a C100 and C246 disulfide. 
(A) A C100-C246 disulfide is visible between the large and small subunits in a crystal structure of 
caspase-7 with an uncleavable peptide inhibitor bound in the active site. 2Fo-Fc density contoured at 
1.0 ) is shown. (B) Sequence alignment of caspases in the region of C100 and C246. The potential 
disulfide linking the large and small subunits is unique to caspase-7. 
Our first design attempt was the substitution R210C. Purification of the single R210C 
variant was not successful, due to low protein yields. We speculated that the formation of 
mixed disulfides may have contributed to low protein yields. 
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We found that removal of one native cysteine, which improved protein yields and eased 
analysis was essential. Caspase-7 is unique among caspases in that it contains a potential 
disulfide interaction between residues 100 (large subunit) and 246 (small subunit) (Figure 
18 B). We engineered out the native C100-C246 disulfide by making the C246S 
substitution.  C246S had similar catalytic parameters to wild-type (Table 1). We 
combined this with the disulfide locking R210C substitution. The doubly substituted 
variant (R210C/C246S) had good catalytic activity and exhibited KM and kcat very similar 
to wild-type (Table 3, Figure 20).  
 
Figure 20: Kinetics curves for caspase-7 WT, C246S, R210C/C246S 
Raw RFU (relative fluorescence unit) data for substrate titration of caspase-7 WT, C246S, and 
R210C/C246S in both 5 mM BME and 10 mM DTT. Michaelis-Menten curve fitting was applied 
to determine kcat and Km with protein concentration held constant.  
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Table 3: Kinetic parameters for caspase-7 WT, C246S, R210C/C246S 
Measured kinetic parameters for WT, C246S, and R210C/C246S do not show significant variances, 
suggesting the mutations do not have an effect on enzyme kinetics. Similarly, while overall 
enzymatic rate increases in the presence of higher concentrations of reductant, the increase is 
statistically identical between WT and R210C/C246S.  
The observed differences between 5 mM and 10 mM DTT can be attributed to the fact 
that DTT has a higher reduction potential. In cysteine-histidine proteases an oxidized 
cysteine would disable the catalytic activity, as mechanism is dependent on the histidine 
abstracting a proton creating a reactive thiolate. The stronger reductant present eases the 
formation of this thiolate species and helps to facilitate the reversal of the tetrahedral 
covalent intermediate by H2O increasing the apparent activity of caspase-7.  
Observation of the designed disulfide dimer.   
The variant R210C/C246S is designed such that mildly oxidizing conditions should drive 
formation of a disulfide, locking the two L2’ loops together across the dimer interface 
and allosterically inhibiting caspase-7. Because the L2’ loops are the N-termini of the 
small subunits, formation of the inactivating R210C-R210C disulfide will generate 
covalent small subunit dimers. To measure formation of small-subunit dimers, we 
exposed wild-type or R210C/C246S caspase-7 to native (reducing conditions) or mildly 
oxidizing conditions (300 µM cystamine). The bands on a denaturing acrylamide gel 
were unambiguously identified by a combination of mass spectrometry and 
Table 1. Kinetic parameters for caspase-7 variants 
 5 mM BME  10mM DTT 
 WT  C246S  R210C  C246S  WT  R210C C246S 
kcat (s-1) 0.36 ± 0.01  0.33 ± 0.01  0.40 ± 0.01  2.42 ± 0.07  2.46 ± 0.06 
Km (µM) 23.98 ± 2.02  21.46 ± 2.77  22.65 ± 2.85  41.87 ± 4.15  39.36 ± 3.42 
Kinetic parameters are based on substrate titrations measured from independent triplicate dilutions of 
substrate on two days. !
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imunoblotting with antibodies specific for the large or small subunits of caspase-7 
(Figure 21, Figure 22).  
 
Figure 21: Incubation of caspase-7 R210C/C246S under oxidizing condition results in formation of a 
unique disulfide between the two small subunits of caspase-7. 
(A) Domain structure and molecular weights of WT or R210C caspase-7. (B) WT and 
R210C/C246S caspase-7 were incubated in native conditions (2 mM DTT) or in oxidizing 
conditions (300 µM cystamine) then analyzed on a coomassie-stained SDS gel or by western blot 
with a caspase-7 anti-large subunit or anti-small subunit antibody. The three gels were merged with 
the anti-large subunit signal colored blue and anti-small subunit signal colored red. The two small 
subunit bands in the native conditions are alternatively cleaved versions of caspase-7, with 
cleavages at naturally occurring residues 199 or 207. 
Caspase-7 has two major auto-activating cleavage sites in the intersubunit linker at 
residues 198 and 206 (Figure 21 A). In wild-type caspase-7 the intersubunit linker 
(residues 199-206) is removed so the prodomain-deleted large subunit is composed of 
residues 24-198 and the small subunit consists of residues 207-311. For our designs, we 
used a construct that allows constitutive expression of the two-chain (active) form of 
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caspase-7. R210C/C246S caspase-7 was produced as two polypeptides of residues 1-198 
and 199-311.  In addition to removal of the prodomain, the large subunit was also 
processed at a minor cleavage site (residue 192, which has been extensively probed by 
Denault and co-workers90) generating some large subunits composed of residues 24-192. 
The small subunit of R210C/C246S appears in two forms (Figure 21 A,B), both with the 
intersubunit linker (residues 199-311) and without the intersubunit linker (residues 207-
311). Under oxidizing conditions the C100-C246 disulfide can be observed in wild-type 
caspase-7 as a large-small dimer as a minor product. Importantly, the expected small-
subunit (small-small) dimer band is strongly formed in R210C/C246S, but is not 
observed in wild-type caspase-7. This demonstrates that the designed dimer forms as 
expected but spurious and random disulfides do not form. The small-small dimer could 
also be readily observed by mass spectrometry (Figure 22, Table 4).  
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Figure 22: The small-small subunit dimer can be observed by mass spectrometry  
R210C/C246S was incubated in the presence or absence of oxidant (1.5 mM cystamine) then 
analyzed by mass spectrometry. (A) In the absence of oxidant clear ions for the large subunit (blue) 
and the two cleavage variants of the small subunit (red, residues 199-311; green, 207-311) were 
observed. (B) In the presence of oxidant, identical ions were observed for the large subunit (blue). 
For the small subunits twice as many ions were observed indicating a doubling of the molecular 
weight due to dimerization of the 199-311 species (red). A hybrid small subunit dimer between the 
199-311and the 207-311 species (green) is also observed. 
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Table 4: Tabulated MS deconvolution ion data of R210C/C246S  
Tabulated deconvoluted ions from the R210C/C246S mass spectra collected in the presence and 
absence of oxidant.  Observed protein masses and corresponding mass to charge (m/z) states are 
listed.  All deconvolutions were gated for masses between 10kD and 30kD. 
Table S1. Tabulated deconvoluted ions from the R210C/C246S mass spectra collected in the 
presence and absence of oxidant.  Observed protein masses and corresponding mass to charge 
(m/z) states are listed.  All deconvolutions were gated for masses between 10kD and 30kD.  
No Oxidant   Oxidant 
        
Mass (avg.) m/z Charge (z)   Mass (avg.) m/z Charge (z) 
19718.0     19718.7   
 705.2 28    705.3 28 
 731.3 27    731.3 27 
 759.4 26    759.4 26 
 789.7 25    789.8 25 
 822.6 24    822.6 24 
 858.3 23    858.3 23 
 897.3 22    897.3 22 
 940.0 21    940.0 21 
 986.9 20    986.9 20 
 1038.8 19    1038.8 19 
 1096.4 18    1096.5 18 
 1160.9 17    1160.9 17 
 1233.4 16    1233.5 16 
 1315.4 15    1315.5 15 
 1409.5 14    1409.5 14 
 1517.8 13    1517.8 13 
 1643.9 12      
 1793.6 11      
        
13133.1     26265.7   
 730.6 18    730.6 36 
 773.5 17    751.6 35 
 821.8 16    773.4 34 
 876.6 15    796.9 33 
 939.1 14    821.8 32 
 1011.3 13    848.3 31 
 1095.4 12    876.5 30 
 1194.9 11    906.7 29 
 1314.3 10    939.1 28 
 1460.2 9    973.8 27 
 1642.7 8    1011.2 26 
      1051.6 25 
      1095.4 24 
      1143.0 23 
      1194.9 22 
      1251.8 21 
      1314.3 20 
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Under reducing conditions only monomeric large and small subunits of R210C/C246S 
were observed. Under oxidizing conditions, small-small dimers were readily observed, 
further confirming the success of the design. Interestingly, both homo-dimers and hetero-
dimers of the two small subunit cleavage variants are observed. For this design to be fully 
successful it is essential that small-small dimers can strongly form, inactivating 
R210C/C246S, and subsequently be reduced, resulting in the return of full activity. 
Inactivating disulfide forms reversibly  
R210C/C246S can be inhibited under mildly-oxidizing conditions (Figure 23) in a 
manner that is consistent with observation of the small subunit dimers (Figure 21, Figure 
22).  
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Figure 23: Disulfide bond formation induces the allosterically inactive state of caspase-7, which can 
be reactivated by the presence of reductant. 
Caspase-7 proteolytic activity was monitored in the presence of increasing concentrations of 
oxidant (cystamine). (A) Oxidation of the R210C is capable of inactivating R210C/C246S at much 
lower concentrations than the active site can be oxidized in wild-type caspase-7 (WT). (B) In the 
presence of reductant (10 mM DTT) full activity is recovered. Data is based on activity assays 
measured from independent duplicate data sets on two separate days.   
Inactivation of oxidized R210C/C246S can be monitored either directly by assaying 
cleavage of a fluorescence substrate (Figure 23), or indirectly by observing that cleavage 
at the 192 site is slowed only under oxidizing conditions (Figure 21). We tested the 
reversibility of R210C/C246S inhibition by incubation in reductant at a roughly 
intracellular redox potential. R210C/C246S was able to fully recover from oxidation-
induced inhibition. Inhibition of wild-type caspase-7 is likely the result of mixed 
disulfide formation between the catalytic cysteine and the cystamine oxidant, which has 
previously been reported91 and is also fully reversible under these conditions.  
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We observed caspase-7 R210C/C246S in an active conformation in the crystal structure. 
There are two possible explanations for why the oxidized form of the enzyme was not 
observed. One is that the latent presence of month old DTT (2mM) from the purification 
was not sufficiently overwhelmed by 1.5 mM oxidant, as was seen in the mass 
spectroscopy experiment. This would have resulted in the reduction of the disulfide 
during crystallization, though we consider this unlikely. A second possibility is that the 
disulfide was reduced by synchrotron radiation, and we discuss that possibility here.  
 
Figure 24: Caspase-7 R210C/C246S can reversibly attain the active conformation. 
(A) Oxidized R210C/C246S was crystallized but was reduced prior to or during data collection. 
Reduced caspase-7 R210C/C246S (3R5K, green) attains a conformation like that of WT caspase-7 
bound to substrate (1F1J, purple) with L2 and L2’ in the up conformation interacting across the 
dimer interface. This is in contrast to the allosterically inhibited conformation of caspase-7 (1SHJ, 
yellow) in which the L2’ loop is folded over the allosteric site and the two L2’ loops make contact 
with one another.  (B) The catalytic residues H144 and C186 are in a conformation that is close to 
ideal for catalysis. Additional 2Fo-Fc density contoured at 1 ) density was observed in the S1 
pocket was modeled as a formate molecule from the crystallization solution. The density around the 
catalytic cysteine (C186) was larger than one cysteine residue. It was best modeled as two cysteine 
conformations each with 50% occupancy. (C) 2Fo-Fc density contoured at 0.8 ) for R210C. (D, E) 
2Fo-Fc density contoured at 1 ) for R210C/C246S (D) and wild-type (E) caspase-7 
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We solved the structure of R210C/C246S in two independent crystals (Table 5). In the 
structures from both of the crystals it was clear that the R210C disulfide had been 
reduced. We were pleased to see that as was the case for chemical reductants, the R210C-
R210C disulfide could be reversed in the crystal by ionizing radiation, allowing the L2’ 
loop to adopt the active conformation (Figure 24 A). This was not surprising, as ionizing 
radiation has been reported to reduce disulfides92. The radiation applied to the crystal at 
the APS synchrotron x-ray source has a flux on the order of 1019 photons/sec/mm2. It has 
been reported that sources with flux of 1015 photons/sec/mm2 can induce disulfide 
reduction and global protein relaxation93.  In an attempt to observe the disulfide-
containing form of R210C/C246S we limited x-ray exposure to one second with the APS 
24-ID-C x-ray beam attenuated to 7% and solved the structure using the minimal data 
necessary (30 degrees of data, 20 frames, 1 sec/frame, 83% completeness). Even with 
only 20 seconds total exposure to the crystal, we were unable to observe any oxidized 
disulfide, suggesting that the inactivating disulfide is quite labile. We can roughly 
estimate the lability of the R210C disulfide by comparison to other caspase-7 disulfides 
that do withstand x-ray interrogation. DICA and FICA, which bind to caspase-7 via 
disulfides with C290, withstand x-ray radiation and are visible in the crystal structure42. 
The disulfide linking the large and small subunits of caspase-7 (C100-C246) also 
withstands x-ray radiation under certain conditions (Figure 19). Thus of the three types of 
disulfides observed to date in caspase-7, the R210C disulfide may be the most labile. All 
caspase-7 structures observed to date show the same crystal packing arrangement. 
Regardless of the loop conformation, the active-site loops always point toward the large 
solvent channels. Thus it is not surprising that the loop reorganization we observed 
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between the oxidized, disulfide-locked R210C/C246S and the reduced, unlocked form 
can be accommodated and interconverted within the same crystal. 
 
Diffraction Data 
 
Native Data set 1 
 
Native Data set 2 
  
Wavelength (Å) 
 
0.9792 
 
0.9792 
  
Resolution Range  (Å) 
 
48-2.86 
 
48-3.1 
  
Oscillation Range per frame 
 
1.0° 
 
1.5° 
  
Measured reflection (n) 
 
106848 
 
28496 
  
Unique reflections 
 
20763 
 
17353 
  
Completeness (%) 
 
99.2 (97.2) 
 
83.6 (87.9) 
  
Redundancy 
 
5.2 (4.7) 
 
1.6 (1.6) 
  
<I/!I> 
 
16.0 (2.7) 
 
16.4 (2.0) 
  
Space Group 
 
P3221 
 
P3221 
  
a = b (Å) 
 
89.85 
 
89.98 
  
c (Å) 
 
185.91 
 
185.11 
  
# = " (°) 
 
90 
 
90 
  
' (°) 
 
120 
 
120 
Rsym 12.7 (69.6) 9.1 (69.4) 
       
 
Refinement Statistics 
    
  
Atoms (n) 
 
3900 
  
  
Water molecules 
 
103 
  
  
Rwork (%) 
 
18.81 
  
  
Rfree (%) 
 
25.13 
  
  
RMSD bond length (Å) 
 
0.010 
  
  
RMSD bond angle (°) 
 
1.197 
  
  
Average B-factor (Å2) 
 
58.93 
   
Table 5: Crystallographic and Refinement parameters of R210C/C246S 
Data in parenthesis are for the highest resolution shell 
Catalytic site geometry  
The reduced form of R210C/C246S is in a conformation that is primed for substrate 
binding (Figure 24). Typically, in the absence of an active site ligand, the L2’ loop is in a 
catalytically inactive conformation39 similar to the allosterically inhibited form42 (Figure 
24 A, yellow spheres). In our structure the presence of formate at high concentrations 
(2.1M) in the crystallization buffer is sufficient to nucleate formation of the substrate-
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binding conformation (Figure 24 A, green and purple spheres). Here formate serves as a 
surrogate for the aspartic acid that normally occupies the S1 pocket (Figure 24 B). 
Because structures of caspases in the active conformation have always been solved in the 
presence of the covalent inhibitor, a structure of WT caspase-7 with formate in the active 
is not available. Based on evidence in which a similar phenomenon has been observed for 
caspase-1 where malonate assists in refolding caspase-1 and serves as a mimic for 
aspartic acid bound in the active site94. Although the structure of wild-type caspase-7 has 
not been determined in formate-containing conditions, we believe that WT protein would 
exhibit a similar substrate-binding groove structure, nucleated by formate,  in the 
presence of high concentrations of formate.  
In R210C/C246S the catalytic dyad (H144 and C186) are in a closer to optimal 
arrangement for catalysis (3.6Å) that has not been observed before in caspase-7. Papain, 
another cysteine protease, has been reported to have a cysteine-histidine distance of 3.2Å 
in a high resolution crystal structure, while computational methods have determined 3.0-
3.3 Å to be the optimal distance for catalysis95,96. All previous caspase-7 structures in 
which the substrate-binding loops are ordered relied on covalent modification of the 
catalytic cysteine37-39,41,42,61,88 and therefore had H144-C186 distances that were too great 
(typically ~5.5Å) to support necessary proton abstraction. The density for the catalytic 
thiol is not unambiguous. We have modeled this density in several ways including 
positioning a water in one lobe of the density. The unfavorable angle of the hydrogen 
bonds for water suggested to us that this is not a water molecule. Therefore, we 
concluded that two conformations of the catalytic thiol may be a more accurate 
representation. We have thus modeled the density as a 50% mixture of two thiol 
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conformations (Figure 24 B) though the thiol position nearest the histidine is 35° from an 
ideal rotamer. R210C is near the N-terminus of the small subunit. In caspase-7, it is 
typically only possible to observe residues starting at residue 212, due to disorder of the 
N-termini. It is therefore not a surprise that the density is weak, nevertheless we were 
able to visualize and build R210C (Figure 24 C). It was also possible to visualize the 
substitution in our design, C246S (Figure 24 D). C246S is in a different conformation 
than C246 locked into a disulfide by an uncleavable peptide (Figure 24 E).  
Discussion 
The disulfide bond is a useful protein-engineering tool since it can form covalent, redox-
controllable bonds at discrete locations from naturally occurring amino acids. Since the 
advent of site-directed mutagenesis, introduction of disulfide bonds has been a well-used 
tool for controlling protein conformation. Engineered disulfides have been used to 
examine functional mechanisms97,98, stabilize proteins99,100, understand allosteric 
coupling101,102 and even to trap transition states103. Redox reversible switches have been 
developed in a number of proteins including measles virus F protein104, malate 
dehydrogenase105, integrins106, kinesin107 and the OxyR transcription factor108,  among 
many others. We sought to build upon this rich history and design allosterically 
controlled caspases, a class of proteins capable of regulating life and death of cells.  
The criteria that guided the rational design of redox activatable caspase-7 included: (1) 
motion of the L2’ loops should be restricted by disulfide-bond formation; (2) the catalytic 
efficiency of the untreated protein should mirror that of the wild-type enzyme; (3) full 
oxidation of the disulfide should result in full inhibition of caspase-7 under extracellular 
redox environments and (4) introduction into intracellular reducing conditions should 
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result in full recovery of proteolytic activity. Caspase-7 is a dynamic protein in which 
loop arrangement plays a key role in activation of the enzyme. In our designed variant 
R210C/C246S, we placed the inactivation switch at the heart of a critical, active-site loop 
bundle.  In the down confirmation, with the L2' loop pinned over the allosteric cavity, the 
substrate binding groove is not formed so the protein is unable to bind substrate or 
catalyze the peptide cleavage reaction. By placing the disulfide over the allosteric site at 
the intersection of the L2’ loops, we can enforce a naturally occurring inactive state using 
native-like redox conditions. In R210C/C246S we fulfilled all of the design criteria. In 
vitro activity results and the observation that oxidation of the R210C disulfide could also 
prevent self-processing at the minor D192 processing site both suggest ready inhibition 
by disulfide formation. The crystal structure of R210C/C246S that was first oxidized and 
then re-reduced in the crystal demonstrates the successful reversibility of our design. 
Finally the observation of small-subunit dimers points to the inhibition mechanism by 
covalent locking of the L2’ loops.  
Engineering in redox switches in a critical region like the active-site loops bundle could 
be a risky proposition. We had previously interrogated residues 211-215 in the L2’ loop 
and found that they were amenable to substitution88. By extension, we hoped that R210 
would likewise be amenable to substitution without negative functional effects. 
Fortunately, this was the case. All caspases have mobile active-site loops. Although this 
endeavor used caspase-7 as a template, the approach of pinning the L2’ loops should be 
applicable for any caspase since the active site loops of all caspases are mobile prior to 
the binding of substrate. Residue 210 is not highly conserved so this position should be 
amenable to this substitution across the family. Intriguingly, residue 210 is natively a 
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cysteine in caspase-3, begging the question of whether caspase-3 uses formation of this 
potential disulfide as part of its unique regulatory mechanisms. In a very high resolution 
structure of caspase-3, the L2’ loop is seen to wrap around the opposite half of the dimer 
with C210 attaining two solvent accessible conformations33. Because caspase-3 has not 
been crystallized in the absence of a substrate-mimic nor in the allosterically inhibited 
conformation, the best model of what this region might look like is the allosterically 
inhibited structures of caspase-7 where the 210 residues make the closest approach. Thus 
it may be possible to make a loop-locked version of caspase-3. It is intriguing to envision 
controlling the activity of an engineered, constitutively active and uninhibitable version 
of the caspase-3 zymogen34 using our loop-locking design. Thus there are many 
possibilities for designing loop-locked caspases. Induction of apoptosis by treatment with 
a variety of allosterically loop-locked caspases should therefore be possible given 
appropriate means of delivery. 
Breakthroughs in targeted nanoparticle and polymer design have begun to make delivery 
of a much wider range of protein-based drugs feasible (for review109).  Active targeting of 
nanoparticles, polymers, dendrimers, and nanogels can be achieved using disulfide 
functionalization, with the prospect of delivering encapsulated payloads including both 
small molecules and proteins. The combination of caspase-7 R210C/C246S with a redox-
triggered delivery vehicle is therefore an intriguing prospect. If R210C/C246S were 
encapsulated in a redox-activable nanocarrier, in the relatively oxidizing extracellular 
environment, R210C/C246S should remain inactive and inaccessibly encapsulated.  Upon 
introduction into the reducing cytosolic environment, the redox sensitive delivery device 
would release R210C/C246S (Figure 25). Liberated R210C/C246S could then likewise 
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be reduced, regain function and activate apoptosis, leading to cell death. This scheme is 
particularly promising in cancers and proliferative disorders, where suppression of 
apoptosis is nearly always a contributor to the evasion of cell death pathways. 
 
 
Figure 25: Delivery scheme for caspase-7 R210C/C246S 
Capase-7 R210C/C246S is amenable for use with delivery vehicles (diamonds). We have designed 
the R210C/C246S version of caspase-7 so that under oxidizing extracellular conditions caspase-7 is 
inactive. Upon entry into the cell, reducing intracellular conditions break the R210C disulfide 
yielding active caspase-7, which can cleave intracellular targets leading to apoptotic cell death. 
Materials and methods 
Caspase-7 mutant generation, expression and purification 
Wild-type caspase-7 was expressed from a construct encoding residues 1-303 plus 
codons for the two amino acids LE, then a six-Histidine tag contained in the plasmid 
pET23-b (AmpR) plasmid110.  Expression of caspase-7 variant R210C/C246S was carried 
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out in a constitutive two chain expression system27. Residues 1-198 were followed by a 
TAA stop codon, a second ribosome binding sequence, and residues 199-303, plus 
codons for the two amino acids LE and a six-Hisidine tag contained in the plasmid 
pET23-b (AmpR). Variants in the protein were generated using QuikChange (Stratagene) 
site-directed mutagenesis.  The recombinant protein was expressed in E. coli in 2xYT 
media grown for 18 hours after induction with 1 mM Isopropyl "-D-1-
thiogalactopyranoside at an OD 600 of 0.6.111 Wild-type and mutant caspase-7 variants 
were purified using Ni-affinity liquid chromatography (HiTrap Chelating HP, GE). After 
binding of protein to the affinity column, the protein was eluted with a step gradient from 
2 mM imidazole to 250 mM imidazole. Protein was diluted to 50mM NaCl and then 
purified using a Macro-Prep High Q ion exchange column (Bio-Scale Mini 5mL, Bio-
Rad) with a linear gradient from 50 mM to 500 mM NaCl in 20 mM Tris buffer pH 8.0, 
with 2 mM DTT. Protein eluted in 120 mM NaCl and 20 mM Tris pH 8.0 was assessed 
for purity by SDS-PAGE to be greater than 98% pure, and stored in elution buffer at -
80°C.  
Caspase activity assays 
Enzyme concentrations were determined by active site titration with covalent substrate 
DEVD-CHO (N-Acetyl-Asp-Glu-Val-Asp-Aldehyde, Enzo Lifesciences) in caspase 
activity buffer containing 100 mM Hepes pH 7.0, 10% polyethylene glycol 400, 0.1% 
CHAPS, 5 mM "-mercaptoethanol, and 5 mM CaCl2 using the flourogenic substrate, 
DEVD-AMC (N-acetyl-Asp-Glu-Val-Asp (7-amino-4-methylcoumarin), Enzo 
Lifesciences), Ex365/Em495.  Active site titration samples were incubated over a period 
of 2 hours in 120 mM NaCl 20 mM Tris pH 8.0 at nanomolar concentrations.  Optimal 
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labeling was observed when protein was added to DEVD-CHO solvated in DMSO in 96-
well V-bottom plates, sealed with tape, and incubated at room temperature.  22.5 µL and 
90 µL aliquots were transferred to black-well plates in duplicate, and assayed with 50-
fold molar excess of substrate. For kinetic measurements, 100 nM protein was assayed 
with the range of 0-500 µM DEVD-AMC over the course of seven minutes. Assays were 
performed at 37°C in 25 µL and 100 µL volumes in 96 or 384 well microplate format 
using a Molecular Devices Spectramax M5 spectrophotometer. Initial velocities versus 
substrate concentration were fit using Prism software (Graphpad Software) to determine 
kinetic parameters Km and kcat.   
Enzyme activity recovery assays were carried out using WT and R210C/C246S mutant 
protein buffer exchanged to remove DTT into pH 7.5 10 mM sodium phosphate buffer 
using Viva Spin 3K concentrators (Sartorius Stedim Biotech,). Working at intracellular 
reduction conditions in vitro proved challenging, due to the propensity of caspase-7 
active site to form mixed disulfides with glutathione. As a surrogate, we selected 
cystamine as the oxidant and dithiolthreitol or 2-mercaptoethanol as reductants. The 
reduction potentials of these four redox systems have been shown to be similar112,113. 
Protein was incubated in 96-well format in a range of cystamine concentrations (300 µM 
- 5 µM; 0 µM control) for a period of one hour. Half the volume was subsequently 
transferred to conditions with a final concentration of 10 mM dithiothreitol (DTT) and 
assayed for activity. DTT’s redox chemistry is at equilibrium with cystamine at pH 7.9, 
supporting our use of 10 mM DTT as an adequate substitute for a highly reducing 
intracellular environment.   
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A similar ratio of oxidant to protein was used to treat caspase samples for caspase activity 
assays, immunoblot detection, mass spectrometry and crystallography.  Caspases were 
then diluted to the concentration appropriate for the individual type of analysis. 
Gel electrophoresis and immunoblot detection 
WT and R210C/C246S protein was buffer exchanged using above method into pH 7.5 10 
mM sodium phosphate buffer, then divided into two samples and incubated in the 
presence or absence of 300 µM cystamine for 2 hours.  Samples for non-reducing gel 
electrophoresis were boiled for 10 minutes in Gel Loading Buffer (New England Biolabs) 
lacking DTT, and loaded onto 16% polyacrylamide gels.  Immunoblots of the 
subsequently separated proteins were performed using antibodies specific for caspase-7 
large subunit (SIGMA Monoclonal Anti-caspase-7 C1104) and small subunit (SIGMA 
Anti-caspase-7 PRS3465) and compared against known size standards (Kaleidoscope 
protein marker, BIO-RAD).  False color merged photographs were generated by contrast 
enhancement then selective color replacement (Adobe Photoshop).   
Protein mass spectroscopy 
Protein for mass spectrometry was prepared at 18 µM in 120 mM NaCl, Tris pH 8.0 and 
2 mM DTT with or without 1.5 mM cystamine.  Mass spectra were acquired on a QStar-
XL (MDS Sciex, Toronto, Canada) hybrid quadrupole/time-of-flight instrument. Reverse 
phase liquid chromatography (Agilent 1100 LC) using a C4 column was utilized to desalt 
and separate excess cystamine. Column output was infused directly into the ESI source at 
a rate of 0.5ml/min using N2 as a nebulizing gas. Protein was eluted over a 10-minute 
gradient from 0%-100% acetonitrile and monitored using UV and TIC. A single protein 
peak eluted between 17-18 minutes at the end of the gradient.  Data was analyzed using 
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Analyst QS (Applied Biosystems) with BioAnalyst extensions. All spectra 
deconvolutions were gated for proteins between 10 kD and 30 kD, with m/z ratios 
between 700 and 1700.  The Mass spectrometers are housed in the Mass Spectrometry 
Center of the University of Massachusetts at Amherst.  
Caspase-7 R210C/C246S crystallization and x-ray data collection 
To prepare R210C/C246S crystals, protein in a buffer containing 120 mM NaCl and 20 
mM Tris pH 8.0 was concentrated using Millipore Ultrafree 5K NMWL membrane 
concentrators (Millipore) to 6.3 mg/mL as assessed by absorbance at 280 nm. Cystamine 
was added to a final concentration of 1.25 mM. Crystal trays were setup at room 
temperature and grown in 3 µL hanging drop with mother liquor consisting of 2.1 M 
sodium formate, 300 mM and sodium citrate pH 5.0 in a 2:1 ratio of protein to mother 
liquor. Crystals grew to a maximum of 180 µm in 3 days at 20 degrees. Crystals were 
cryoprotected in 20% ethylene glycol in mother liquor with a 60 second incubation, then 
frozen by rapid immersion in liquid N2. Data were collected using synchrotron radiation 
at APS 24-ID-C over 90 frames with 1° oscillations and showed diffraction data to 
2.86Å. Indexing and integration were carried out with MAR XDS114. Data were Scaled 
using SCALA74. Data for the low radiation damage crystal were collected using with 1.5° 
degree oscillations. These data were indexed and integrated using HKL200073 and the 
data were scaled using SCALA74. 
Structure determination 
Phase information was obtained by molecular replacement using 1F1J as the search 
model with residues corresponding to L2' omitted during searches with PHASER115. 
Removed residues were rebuilt into unambiguous density using COOT116, then refined 
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using Refmac117 restrained refinement. Water and formate molecules were inserted 
manually and checked for stereochemical appropriateness. The final refined model 
contains residues 57–196, 210–303 for chain A and 357–496, 510–605 for chain B. 103 
water molecules are assigned chain O, and 7 formates assigned chain F. 
Coordinates have been deposited in the PDB with accession code 3R5K 
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CHAPTER IV 
COMPUTATIONAL PROTEIN RE-DESIGN USING EGAD 
Abstract 
Current tools employed in the study the role of individual caspases in apoptosis lack 
specificity, and thus a novel approach by an orthogonal effector will address such a 
limitation. In this work we propose to develop an orthogonal switch technology based on 
a computational redesign of the allosteric site at the dimer interface in caspase-7. This 
will allow for specific control over the function of caspase-7.  Such a technology would 
facilitate the study of caspase-7 target substrates in cellular cultures, without necessitating 
the use of potentially misleading knock-out variants.  The use of a computational system 
allows for the rapid sampling of millions of possible amino acid and molecule 
permutations on very short timescales.  This high throughput sampling has allowed rapid 
in silico evolution of a small molecule binding site which was the objective of this part of 
the thesis. In the future, these designs can be tested by enzymatic studies and 
crystallographic methods.   
Introduction 
Design of orthogonal controls would address the lack of specific inhibition tools available 
for the study of various protein families. The ultimate goal of this approach is to develop 
a robust design and validate the technology on a whole range of caspases. This will allow 
us ultimately to spread this technology to other allosterically controlled proteins. The 
goal of this project was to use computational protein design methods118 to redesign the 
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cavity at the interaction surface of two caspase-7 monomers and introduce specificity for 
a small molecule which would act as an allosteric inhibitor for that particular caspase.  
 
Figure 26: Small molecule effector placed ideally in allosteric cavity. 
A small molecule (doxycycline) has been modeled into an ideal position in the allosteric cavity of 
caspase-7. The allosteric switch tyrosines (purple spheres) are sterically blocked by the small 
molecule from adopting the catalytically competent conformation.  
The allosteric inhibition of caspase-7 by covalently tethered molecules has been 
studied42,81. The next logical step is to use a non-covalent reversible interaction to 
inactivate the protein. Using computational design as a low penalty, high throughput 
iterative design screen, we can combine established molecular biology methods, along 
with crystallography, to develop a model-to-protein-to-crystal design process of the 
protein. This will iteratively lead to a new protein variant that can be controlled 
orthogonally by means of a small molecule used in the design. Our computational design 
will begin with known crystallographic structures of caspase-7, which will be optimized 
for non-covalent binding of a tetracycline-class antibiotic molecule. In this optimization, 
the amino acid sequence that can best recognize the small molecule is computed. After 
the in silico design, the protein can be expressed in E. coli and purified for biochemical 
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characterization and crystallization. The resultant crystallographic data will allow 
refinement of computational models based on actual structural information, and perhaps 
elucidate new pathways for allosteric inhibition by small molecules. 
Directed evolution is the best analogue for a computational design process. It must be 
said that there have been more successes with using directed evolution to engineer in new 
functions to proteins. However, as opposed to directed evolution, computational designs 
allow for screening of 1024 (13 sites per monomer, 17 potential amino acids at each 
position; 2617 ≈ 1024) potential variants per simulation. To effectively screen similar 
numbers of variants using directed evolution is impossible with current technologies, 
which allow for screening of 109-1013 variants maximally. Even to screen these smaller 
numbers of variants would require the development of a robust reporter of caspase 
inactivation, combined with rapid screening methodologies. However, the use of such 
technologies would require significant additional capital and time investment as 
compared to a computational trial. Thus computational protein re-design is the most cost 
effective rapid initial screening method for the introduction of new binding motifs. 
Furthermore, the prospect of combining directed evolution with computational design can 
increase the likelihood of success dramatically.   
Success in protein design and redesign efforts lies in the availability and openness of the 
design platform. Many efforts have been duplicated in the field of computer-based 
protein design, however, the growing popularity of the open source software movement 
may stem this tide. Programs like DEZYMER119 have been historically difficult to obtain, 
with source code not being made available. In the absence of the original source code, the 
inner workings of the energy functions and parameterization are hidden from the 
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operators, keeping the software more single purpose. However, the availability of source 
code does not automatically guarantee a better working environment. Rosetta56, by far the 
most popular current protein-design package, does offer source code, however the 
documentation of the source code is reportedly minimal, leaving the user to reinvent the 
wheel in the process of customizing the software for a novel purpose. On the other hand, 
EGAD118, while not in active development, has been released freely, with extensive 
documentation to allow for easy customization by novice computational chemists. In 
addition, at the time this project was implemented, EGAD was one of the few programs 
that could design proteins against a small-molecule ligand. It is therefore important to not 
only consider the success of the tool used for protein design, but also the availability of 
documentation.  
Existing EGAD toolkit 
EGAD, or EGAD!, a Genetic Algorithm for Protein Design, was developed initially 
Navin Pokala under the direction of Tracey Handel118, and has since been updated to 
EGAD Library, by Arnab Chowdry120. EGAD Library is based on EGAD’s force-field 
implementation and according to the application’s literature, “is intended for end users 
with programming experience, written in C++, for the development of new protein design 
applications.” As an open source and well-documented application, EGAD allows novice 
programmers to develop and extend the current toolset for the users particular interest. 
This full access to the development of the program is very advantageous over other more 
black-box suites, as features and bugs can be worked out. The use of this method allows 
for a high throughput design from the computational model to the expressed protein, and 
ultimately the solved crystal structure of the allosterically inhibited caspase. 
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EGAD’s computational approach relies on structural protein data in the form of a set of 
coordinates in a PDB file along with the structural data of the small molecule. The initial 
starting location of the small molecule, henceforth referred to as the ligand, in relation to 
the protein is preset by the user. Molecular visualization programs such as PyMol79 or 
COOT116 can be used to design this initial small molecule placement based on existing 
knowledge of the allosteric switch in caspase-742. The selection of residues comprising 
the potential binding cavity is similarly chosen.  A variable residue can either have full 
mutability, in that EGAD can choose the best amino acid identity, save for Gly, Pro, Cys, 
and rotamer for that particular position. The second option is to maintain amino acid 
identity at a position, while allowing that particular position to select from the rotamer 
library to optimize the position.  
The selection of ligand is restrained by two criteria. First, desired ligand should have no 
appreciable effects on wild-type caspase-7, and secondly, the ligand must be amenable to 
computational design in that the molecule has few rotatable bonds and the molecule must 
be of appropriate size for the cavity. One potential family of allosteric effectors is the 
tetracycline antibiotic family. Preliminary caspase-7 inhibition studies were carried out in 
the Hardy lab to determine possible tetracycline derivatives that are appropriate for use in 
design. Besides tetracycline, doxycycline, demeclocycline and minocycline were tested 
for their inhibitory effect on the wild type caspase-7 protein. 
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Figure 27: Effects of tetracycline analogs on caspase-7 activity.  
Wild-type caspase-7 was incubated with increasing concentrations of the indicated inhibitors for 
one hour. The activity of caspase-7 was then tested in a kinetic cleavage assay using the 
fluorometric substrate DEVD-AMC. The amount of inhibition is relative to a DMSO control. 
(Figure 27). Demeclocycline showed inhibition of the protein at relatively low 
concentrations through an undetermined mechanism, and so was ruled from further 
investigations. Doxycycline and minocycline both had similar inhibition curves to that of 
tetracycline and thus were considered for further study using EGAD. Doxycycline has 
been chosen as the most likely candidate for allosteric effector.  
 
Figure 28: Potential small molecule effectors 
The length of the potential small molecule effectors is of interest since the effector must effectively 
fill the cavity of caspase-7. 
[Analog] µM Drug 
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To produce a small-molecule starting model for future designs, the low energy structure 
of each small molecule was determined computationally using Hartree-Fock type ab 
initio calculations to the RHF-6- 31+g basis set using Gaussian 03121. The reliability of 
this calculation was determined by the calculation of the minimum energy structure of 
tetracycline, and comparing it to that of a solved crystal structure that included 
tetracycline in complex with the ribosome, with the two results being very similar. 
EGAD Computation Setup 
EGAD is a command line driven program with no graphical user interface, and so all 
commands and input must be hand coded into input files. The input file generation for 
EGAD is by far the most time consuming of steps prior to calculations. The small 
molecule’s molecular description consists of a ligand input file and a ligand parameter 
file, which contains all the atomic coordinates, the atom types, atom charges, and inter-
atomic connectivity. Atomic coordinates are represented as X, Y, Z and are in the same 
space as the protein.  Atom type is for the OPLS force-field122 and the atom type is 
assigned manually at the discretion of the user. The atom type depends on the atomic 
environment in which the atom resides. Atomic connectivity is self-explanatory and 
charges are calculated during the energy minimization step of the geometric optimization 
in the ab initio calculation of the structure of the ligand. Rotatable bonds can be described 
in EGAD, however this feature is of limited use as the bonds can only be described as a 
set of three rotations about a fixed atom. 
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Figure 29: EGAD operation flow 
Files containing atomic coordinates and atomic descriptors for both the protein and small molecule 
ligand are input into EGAD for energy tabling. The energy table is then loaded into an energy 
minimizer, which uses DEE and Monte Carlo methods to search for an energy minimum. Once 
sufficient solutions are found, the data is then output as coordinate files in the form of PDBs.  
The second file that describes the ligand is the ligand input file.  This file calls the ligand 
parameter file at the start of the calculation, and includes the coordinates of the centroid 
of the molecule. The centroid is calculated by finding the mean of all the discrete 
coordinates of the atoms within the ligand. The input file includes the variables for 
allowed ligand translation (spread_radius) and allowed ligand rotation (XYZ_Range). 
The allowed ligand translation variable sets how far from the initial centroid coordinates 
the calculation is allowed to move the molecule (in Angstroms), while the ligand rotation 
variable allows for control of the rotation range (in radians) in the calculation.  
EGAD General Energy Function 
During computational redesign, each variant is scored by the EGAD energy function.  
EGAD’s energy function is a linear combination of the calculated energy of the statically 
held backbone atoms ("Gi_bkbn), the energy of the particular rotamer at position i 
(%Gi_internal) and the pairwise interaction of rotamers at positions i and j  ( !!!"!!!! ).  
Protein PDB 
Associated Input file 
includes other input file 
locations 
Ligand Input 
Parameters 
Atomic coordinates 
Atom type 
Ligand placement in space  
Rotation, translation allowances 
Energy Tabling 
Minimizer Output PDB 
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Each portion (ie each term) of the equation is further expanded to the vacuum energy and 
solvation energy components. The vacuum energy consists of the VdW, Coulombic, 
Torsional correction terms, while the solvation energy consists of Generalized Born 
calculation.   
(Note: %G is the modified Gibbs free energy equation, while the E represents a free 
energy approximation, as the entropy term has been omitted in the calculation.)   
( ) !!!
>
"+"+"="
i ij
ij
i
ii GGGG bkbn__internal
 
Figure 30:Total Energy calculation term 
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Figure 31: van der Waals, Coulombic electrostatic potentials and torsional potential 
 
It is worthy to note that bond stretching and angle bending terms are not taken into 
account in this calculation, because the model assumes a rigid backbone and uses 
idealized rotamer conformations.  To reduce computational overhead, long range 
interactions (greater than 10Å) are ignored.  Dielectric constants were chosen empirically 
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to a value of 8.0.  Again, we have atoms i and j , with !!", with charge !!, being the radial 
distance between the two, and !!"!! !!" ! !!!! being their dihedral angle, VdW equilibrium 
distance and well depth respectively.  Lastly, in the torsional potential term there is a !!!" 
term which represents the Fourier series coefficients for torsional energies.   
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Figure 32:Generalized Born model used in EGAD 
 
In the equation above, the Born radii are calculated from the supplied protein structure.  
Where !! is Coulomb’s constant, i and j are the atoms, with r being the distance between 
said atoms. We take into account two dielectric constants, that of the molecule (!!), and 
that of the surrounding solvent (!!), along with the individual charge of each atom i (!!) 
with a Born radius of !!. The screening interactions are described by !!".  
The energy terms only apply to the protein, and not to the small molecule, the small 
molecule is a rigid structure, whose conformation was determined by energy 
minimization using in vacuo ab initio methods, specifically the 6-31+g basis set of the 
restricted Hartree-Fock calculation by Gaussian 03121.  
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EGAD Efficiency  
EGAD’s efficiency stems from the architecture of the calculation. The energies of all the 
possible combinations of rotamers and mutants for the selected amino acids are 
calculated and stored. The precalculation of energies, though space inefficient, allows for 
rapid energy lookup.  
The low energy search algorithm employed by EGAD in our experiments uses a 
stochastic approach found in Monte Carlo simulations.  The Monte Carlo search allows 
us to sample rapidly a large energy landscape that has been parameterized in the previous 
tabling step.  Monte Carlo methods sample the local energy space until a local minimum 
is found, and with large number of attempts, this local minimum is assumed to be the 
global energy minimum.  Dead end elimination has also been implemented in the energy 
minimizer, though its use is limited to initial pruning prior to Monte Carlo minimization. 
The greatest limitation is the necessity to maintain rigidity of the backbone atoms during 
the calculation. Because of the complexity of including backbone flexibility in the 
calculation, certain restrictions and compromises must be made to make the calculation 
feasible. The van der Waals radius scaling factor, is variable between 90% and 95%, to 
account for small backbone rearrangements.  
SURFNET 
The torrent of data following an EGAD run is difficult to parse without context. In a 
typical calculation, between five and 100 output structures can be generated, each with a 
different final energy and amino acid composition at the variable sites. The minor energy 
variations between each solution are not necessarily meaningful, as composite 
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assumptions within the calculation lead to large error bars. Thus a secondary screening 
methodology is required to further determine the best result.   
To create the best binding cavity for the small molecule, additional space surround it 
must be minimized. As a secondary screen, the output from EGAD is processed via 
SURFNET123 which generates molecular surfaces of molecules, and can find voids 
between the protein and the small molecule. SURFNET is freely available online 
(http://www.ebi.ac.uk/thornton-srv/software/SURFNET/) to academic institutions, and 
has been installed on the lab linux workstation Solitude. SURFNET processes a single 
output file individually, as determined by the input parameter file associated with 
SURFNET (surfnet.par), and outputs a series of files that contain geometric information 
of the voids between the protein and ligand, among others.  SURFNET has other 
functions such as cleft detection, and numerous geometric rendering options, however 
these are beyond the scope of this thesis.  
Running EGAD & SURFNET 
EGAD runs are composed of a series of terminal commands, and can be easily batched 
together. For data separation simplicity, each run of EGAD performed is within a 
serialized directory structure. For instance, the directory doxdes3.2.11 indicates a design 
run using the doxycycline ligand, third generation of major design principals, second set 
of experiments, 11th variant on input parameters.  This directory structure is meant as a 
guide for simplification of data analysis, and specifics are likely to change from run to 
run.  Each directory (and therefore individual run) requires the following files. 
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common_inputs directory 
 This directory contains the rotamer libraries, Van der Waals residue parameters, 
torsional parameters and atom specific information as part of the Van der Waals radii for 
the OPLS forcefield, and test points for the SASA calculation.  As this directory may be 
modified between runs, it is useful to reference a local copy within the directory structure 
for each run.  These files are called by the protein input file component of the EGAD 
setup.  
etable.cmdline 
Etable.cmdline contains the flags for EGAD that specify the protein input files, the ligand 
input file, and whether WT residues are allowed.   
 
Figure 33: etable.cmdline 
 
In this example, the EGAD protein input files are called by 1SHJ_A&B.input, the ligand 
file is called by dox.liginput, and WT residues and rotamers are implicitly allowed.   
1SHJ_A.input 
For this example, we are using separate protein files for each side of the dimer to allow 
each side to be addressed and varied independently.  The first file called contains calls to 
files and parameters for the protein component of the run. The critical flag of the file, 
TEMPLATE_PDB refers to the location of the PDB input file. This file should be in the 
directory of each run, and in this example, specifies the A chain of 1SHJ.pdb 
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Figure 34: Protein component input parameters 
The first file loaded by etable.cmdline contains protein component input parameters such as the 
location of the PDB that stores the geometric coordinates (TEMPLATE_PDB), and the variable 
positions within that PDB.  
The VARIABLE_POSITIONS flag refers to the residues that are specified for 
computation. In the example (Figure 34), only residue at position 223 is included, forced 
into tyrosine (TYR), and only with rotameric freedom. This calculation will allow the 
ligand to move, position 223 to sample rotamers, with the remaining residues held fixed. 
If a specific mutation is called for, or only specific residues allowed, the allowed residues 
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can be listed in comma delimited format. The flag ‘all’ will allow any residue type, 
except glycine, cysteine and proline (Figure 35).  
 
Figure 35: Variable positions in EGAD 
Variable positions explicitly called by the protein parameter input file. Positions not listed are 
modeled as listed by the PDB geometric coordinates, but not varied, nor allowed to move.  
Notations after hash (#) are ignored by EGAD, and can be used as comments for the user. 
The 1SHJ_B.input file only contains the location of the B PDB, and variable positions in 
that PDB.  
Machinefile 
This file is only called when running in an MPI parallel processing cluster 
environment124, and contains machine names on which to run. All EGAD simulations to 
date have been run on either the generously provided Handel pandemonium cluster at 
UCSD or the compbio cluster at the University of Massachusetts, Amherst.  
Dox.liginput 
The contents of this file refer to the ligand parameter file, and also mark the initialization 
coordinates for the ligand.  Under the location flag, the coordinates listed are the center of 
the ligand, and can be calculated by averaging the X Y and Z components separately 
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from the ligand parameter file.  The Spread Radius refers to the distance in Angstroms 
the ligand moves from the initial location, while the grain is the number of steps the 
ligand will make in each axis.  The rotation and range flags indicate the number of 
rotations to make about each axis, and the range, in radians, which rotations should be 
made.  
Dox.ligparm  
The ligand parameterization is contained within this file.  In this specific example, the file 
contains necessary information to define doxycycline. Layout of this file is reminiscent to 
a PDB file, in that the file is in a space-delimited format. Column 1 contains the flag for 
coordinates, followed by atom number, atom identity, then atom type. The atom type is 
for the OPLS forcefield and needs to be determined by finding the closest atom type in 
the forcefield file that describes that atoms chemical situation.  The column composed 
primarily of 0’s refers to the rigidness of that atom relative to other atoms connected to it. 
Following this column are three columns of X Y and Z coordinates that allow atom 
distance information to be calculated. The final column is the charge associated with the 
atom, and this information is taken from an ab initio energy minimization calculation.  It 
is important to note that to move the ligand to a new staring position requires that new 
coordinates be entered into this file, and a new center of coordinates be calculated.   
tabling.sc 
This script file builds the master tabling input file from components outline above and 
starts the program called MPIPolymerTable, with the output file being generated in the 
root directory of the script starting location.  
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Figure 36: tabling.sc start script 
Tabling initiation script that ensures the proper syntax of a MPI distributed computing run to be 
executed using the etable.cmdline and machinefile files as inputs, while generating a log file 
(etable.log) in the same directory.  
 Stopping this script with the escape character during tabling will not stop the tabling run, 
only halt printing of the tabling log file.  To stop tabling, the job must be killed by PMID 
in the linux process manager on each machine (node) running the tabling.  Running two 
simultaneous tabling jobs in the same directory can lead to corrupted output files, and is 
generally bad practice.  Depending on the input parameters, job size, and available 
computing power, tabling can take between 6-12 hours.  Though the whole set is 
ostensibly parallelizable, the single most computationally intensive segment is the ligand 
parameterization, which cannot be spread between machines.  It is therefore 
recommended that tabling be undertaken on one machine. Output files generated end in 
the file extensions .etable and .groups.   
Monte_carlo.cmdline 
Once tabling is completed, search for the minimum energy value can be done using the 
MonteCarlo program of EGAD.  The random seed is an important variable, and must be 
changed between each run of the same input to ensure MonteCarlo produces independent 
results (Figure 37). The number of runs, saved and number of steps is self explanatory, as 
these parameters determine the length of the random walk, and the number of top 
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solutions to be saved. The penultimate flags in this file refer to the output files from 
tabling.  These files should reside in the same directory as the MonteCarlo run, and so file 
paths are unnecessary.  The final flag in the input file refers to the number of 
DeadEndElimination steps to take. This flag is optional.  
 
Figure 37: monte_carlo.cmdline 
The monte_carlo.cmdline file houses pointers to the tabling output files (etable and groups) and 
specifies the number of runs, how many of those runs are saved, and how many steps per run are to 
be in each Monte_Carlo run. Eliminate 2 refers to the rounds of DEE prior to the start of 
Monte_Carlo.  
montecarlo.sc 
The montecarlo.sc script is very similar to tableing.sc (Figure 36), in that it invokes the 
MonteCarlo program with the proper input files listed (Figure 38).  
 
Figure 38: montecarlo.sc start script 
Similar to the tabling script, this script initiates the minimizer step of EGAD while in a MPI 
controlled multi node environment.  
Struct.sc 
The output file from the MonteCarlo program (monte_carlo.log) contains references to 
the atomic positions that represent the minimum for the run. The script 
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print_structuresnue.py is a python script whose input syntax takes the monte_carlo.log 
file, the protein file and the ligand file to generate PDBs of final output structures. 
Struct.sc calls print_structuresnue.py two times, to generate SASA volumes for the 
protein with and without the ligand in the final conformation present. This feature has 
been primarily deprecated due to the more accurate SURFNET being employed, though 
the additional information from a SASA water roll is useful in some instances where the 
ligand is protruding from the allosteric pocket.   
PRESURF.sc 
The SURFNET program is run after PDB model generation. Modification of the 
surfnet.par file is required to specify the number of atoms within the protein and the 
ligand. SURFNET then calculates the volume between the two bodies using spheres 
between 1.0Å and 4.0Å. The additional options afforded by SURFNET are beyond the 
scope of this thesis, and can be best referenced at the SURFNET website. The presurf 
script generates a new directory, surfout, where the outputs from the SURFNET run are 
subsequently written. Presurf.sc removes all previous run outputs generated by 
SURFNET prior to starting a new SURFNET calculation. 
A successful SURFNET calculation will yield many output files, but the critical files for 
EGAD ligand/protein spacing analysis are surfnet.pdb and volumes.pdb.  Simple 
visualization of the remaining space surrounding the ligand can be accomplished by 
loading the output PDB from EGAD into a molecular viewer such as PyMol along with 
surfnet.pdb. This will generate two sets of MAP points, one corresponding to the small 
molecule, the second corresponding to the surrounding space. 
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Figure 39: SURFNET output displayed in PyMol 
An output solution from EGAD and SURFNET rendered in PyMol. The extra space (cyan spheres) 
surrounds the ligand (green spheres).  Hydrogens not seen in the crystal structure have been added 
where chemically prudent.  
 
To quantify the volume remaining in the cavity, a simple calculation must be done with 
figures from volumes.pdb. During the SURFNET calculation, SURFNET calculates the 
total volume of the ligand+protein, protein only and ligand only.  Remaining volume of 
the cavity is calculated by subtracting the ligand volume from the total volume of the 
complex, then subtracting the result from the volume of the protein only.  
Initial EGAD Designs using Tetracycline 
Initial EGAD designs were undertaken in a close collaboration with Dr. Arnab Chowdry 
and Dr. Tracy Handel of UCSD. Tetracycline was chosen as a ligand design target at that 
time, as an energy-minimized structure for doxycycline was not yet available.   
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Residues selected for inclusion in the first round of design were chosen for their 
proximity and potential interaction with the tetracycline (Figure 40 A, Table 6).  
 
 
Figure 40: Des1.0 binding ligand interaction pocket 
(A) The native interaction pocket with residues included in design (green) labeled. Tetracycline 
(orange) is in the conformation predicted by EGAD. (B) Des1.0, the designed output from EGAD. 
 
Table 6: Design results for Des1.0 at mutated positions 
 
As mentioned in chapter 1, the free rotomeric freedom of the tyrosine at 223 is critical for 
activity.  As such, the results from the first design were troubling in that the adjacent 
residue to the allosteric switch tyrosine 223 was a tryptophan.  The bulkiness of the 
resultant residue, while beneficial to the overall design, posed a potential problem if the 
tryptophan restricted the movement of tyrosine 223. As a first step, the single point 
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mutant F221W was generated (Figure 41 A) and its activity measured relative to wild 
type enzyme (Figure 41 B).  No appreciable difference was noted in both expression of 
the F221W variant, nor in the activity.   
 
Figure 41: Expression and validation of F221W & Des1.0  
Expression and activity validation results for the intermediate design mutant (F221W) and the full 
first generation design (Des1.0). The expression of F221W yielded a protein with expected 
molecular weights (A), and activity recorded was comparable to WT (B). The full mutant design, 
(Des1.0) showed significantly decreased activity relative to WT (B), but behaved just as WT in a 
gel assay.  
The positive result with F221W led to the generation and expression of the full design 
mutant.  However, the EGAD computation resulted in an asymmetric design, which due 
to limitations of current caspase-7 expression systems, was not available.  Caspase-7, 
being a obligate homodimer would require the generation of two independently 
mutateable monomers. The generation of such a expression system construct was 
undertaken, the project remains unfinished.  This technical problem required the 
generation of a design that would be symmetrical about the allosteric cavity. 
Conveniently, the EGAD solution was nearly symmetrical on both sides of the dimer, 
with only position 211 varying. Upon examination of the computational result, it was 
decided that a methionine would be beneficial to include on both sides of the dimer, as 
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opposed to mutation to an alanine. The position of residue 211 near the N-terminus of the 
L2’ loop is considered mobile, as the L2’ loop necessarily requires rearrangement during 
the substrate binding groove formation (Figure 6).  
The full design (Des1.0) was expressed, purified (Figure 41), and assayed against WT to 
assess relative activity. Though the expression of Des1.0 resulted in a protein that 
behaved like WT in both purification and gel assay, the catalytic activity was severely 
impaired (15-fold reduced) relative to WT.  However since Des1.0 was still a somewhat 
functional caspase-7, and given that the primary goal of the design is to engineer in 
sensitivity and binding for tetracycline, we tested this.  To assay tetracycline-mediated 
inhibition, caspase-7 and Des1.0 were subjected to tetracycline to determine IC50 
irrespective of the intrinsic activity (Figure 42). Des1.0 showed a 50% lower IC50 relative 
to WT, demonstrating a partial success in the computational design.  
 
Figure 42: Caspase-7 vs Des1.0 IC50 to tetracycline 
The sensitivity of Des1.0 relative to WT caspase-7 to the target tetracycline molecule is 50% 
higher, suggesting a successful first round of design using EGAD.  
The severely lowered caspase-7 activity of Des1.0 lead to the investigation of L2’ as a 
candidate for design by alanine scanning mutagenesis (Chapter 2). It was subsequently 
discovered that position I213 is of critical importance to the formation of the substrate 
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binding groove, and thus both positions 213 and 212 were removed from subsequent 
design initiatives.   
Designs post Des1.0 
The lessons learned during Des1.0 and further investigations to L2’ loop’s amenability 
for mutation guided later computational designs. Because doxycycline was 1Å longer 
than tetracycline, and could therefore reach between the two Y223 residues on opposite 
sides of the allosteric pocket, doxycycline was used in all subsequent rounds of design. 
The doxycycline structure was subjected to ab initio energy minimization in Gaussian 
03121 and geometric and chemical parameters were input to the dox.ligparam file. 
Additionally, residues 212 and 213 were included in the calculation, but were only 
allowed rotameric freedom.   
A number of variables that included Van der Waals radii scaling, random seed changes, 
included residues, ligand starting position and movement were varied in numerous runs 
with a total of 90 successful solutions compared.  A direct comparison of similar runs, as 
defined by the same residues being varied, can be made and trends from these results can 
be elucidated.  In set one, with 42 solutions across 14 different setups we find where 
certain residues are preferred over others.  For instance residue number 215 in chain A is 
preferred and 89% of the time, while other residues are selected here the remaining 11% 
of the time. However the preference of one residue over another is not always so 
overwhelming, as residue 292 is split between methionine, alanine, and arginine in 
almost equal amounts.  
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The strength of the asymmetric nature of the design is evident when one compares chain 
A to chain B.  Using the example of residue 215, chain A differs from chain B in that 
chain A, glutamate is chosen while in chain B a tryptophan residue is selected 84% of the 
time. It is important to note that these consensus residue selections do not always 
translate across different input parameters. 
 
Figure 43: Consensus residues across one set of solutions. (N=42) 
Percent selection of a specific residue at each the variable design position for EGAD design series 
3.2.x. Percentages are score based on number of occurrences of that residue in all solutions from 
multiple runs.  
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A second set of results (48 solutions from 11 separate runs) differs from set 1 in that 
different residues were selected for mutation and the starting position of the small 
molecule was also changed. The reproducibility of EGAD as a design tool becomes 
evident when one compares two starting positions of the small molecule and the resulting 
consensus residues predicted by the computation. For instance, at residue 215 in chain A, 
the predicted consensus residue is a glutamate, while in the second set at the same residue 
position an aspartate is called for. This suggests that an acidic residue in this position is 
likely to be beneficial for binding of the small molecule. Trends such as these can be 
funneled into subsequent designs, such that position 215 is only allowed to vary to acidic 
residues (Figure 35). Finally, after a few rounds to select for not only residue chemistry, 
but also possibly residue identity, scoring based on residual space in the small molecule 
cavity can be undertaken. 
No computational design result can be discussed without mentioning final energies 
calculated. During the minimization step, when a Monte Carlo simulation is searching for 
the lowest set of pairwise energies, EGAD uses a force field calculation in hartrees to 
score outputs. However, due to the variances and inherent approximations within such a 
calculation, comparison of the direct energy values between runs is not recommended. 
Generally speaking, output energies are on the order of -1900 to -2300 depending on 
factors such as Wan der Waal radii and final position of the small molecule are typical 
from an EGAD calculation. Higher energies, especially if positive, suggest steric 
clashing, which we could observe post-run.  
98 
 
Figure 44: Consensus residues across one set of solutions. (N=48) 
Second set of solutions (3.3.x series) based on a greater number of positions varied and a new 
starting position for the small molecule.  
The remaining space surrounding the small molecule in each design varies based on the 
final ligand position, and the surrounding residues predicted.  Selection of protein   
designs to carry forward for expression in E. coli must be made not simply based on 
consensus residues at specific positions but also their contribution to a smaller binding 
pocket. In the case that a residue does not fall into a consensus, the secondary screening 
for unfilled cavity volume using SURFNET will allow further refinement and selection of 
residues for mutation. 
Using tools like those outlined above can greatly simplify the selection of mutants to test 
experimentally. Experimental validation of these designs has not been attempted due to 
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the inability to express and purify a heterodimeric version of caspase-7. Development of 
a heterodimeric caspase-7 has been undertaken by another graduate student in the lab.  
The results of the calculations presented here, along with source code for EGAD and the 
scripts which automate the computation can be found in the /home/shared/EGAD 
directory on the Hardy linux workstation, solitude.  As of the writing of this thesis, 
EGAD has fallen into disrepair and is not currently accessible on either the UCSD cluster 
or the compbio cluster. Installation and compilation of EGAD from source is possible, 
though directions for this task are beyond the scope of this thesis. SURFNET has been 
installed on the Hardy solitude linux workstation, and can be invoked using the command 
SURFNET in the directory in which the proper input files are located.   
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CHAPTER V 
CONCLUSION 
Caspase-7 is an excellent system to study, as the wealth of knowledge that has been 
gleaned in this work from the investigation of its loop movement, active site 
conformation, and allosteric control can be generalized as a model system for the study of 
other caspases, and even proteases in general. The outwardly unique characteristics found 
in caspase-7 have analogs within the protease family, and work on other proteins can be 
improved based on the findings presented in this thesis.  
Loop or structural rearrangement upon binding of substrates or co-factors is not unique to 
caspases. The classical example is hemoglobin, where a tetramer undergoes a global 
conformation rearrangement as a function of binding oxygen125. In this example, there is 
a large conformational rearrangement change upon binding oxygen that has become a 
hallmark of the protein. Other systems have large conformational changes in their life 
cycle, such as HIV protease, whose flaps open and close depending on binding state126, or 
influenza hemagglutinin, which seems to adopt a ‘spring loaded’ injection mechanism 
during its function127. All these structural rearrangements are required for the protein to 
function. In caspases, there is an intersubunit cleavage that is required for activation, 
implying that either the conformation of the zymogen is not sufficiently flexible to 
undergo catalysis, or that a structural rearrangement is necessary. The best metaphor for 
an executioner caspase is an unloaded pistol. Evolution has designed multiple fail-safes 
to ensure that caspases do not inadvertently activate. In our metaphor, the zymogen 
caspase is an unloaded pistol, ready to accept the ammunition. When cleaved to the 
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mature form, caspases become loaded, ready to fire, but like a pistol, require that 
additional steps be taken to make the mechanism run. This is analogous to the mature 
state of caspases, where the loops are almost ready, but not in a catalytically competent 
conformation. The multiple steps involved, along with the placement of the loops ensure 
that caspases are not inadvertently initiated, a process which would be very detrimental to 
a cell.  
Because of this large rearrangement of loops that compose the active site, the active site 
is naturally more flexible than the core of the protein.  At first blush, the inherent 
flexibility of an active site can be more of a hindrance than a benefit for a protein as 
critical for cell homeostasis as a caspase. It is generally agreed that catalytic sites occur at 
the interfaces of domains or intersubunits128, however, catalysis of reactions by proteins 
requires very specific orientation of the residues involved. The additional support 
afforded by the surrounding structures in proteins at interfaces can rigidify the active site 
to allow for proper geometry to undergo catalysis. Additionally, an interface can present 
a solvent accessible region for the interaction of substrate and enzyme, facilitating the 
capture of substrate and release of product. In the case of HIV-1 protease, the dimer 
interface houses the catalytic residues which remain stationary, while two ‘flaps’ undergo 
conformation changes that move 7Å during substrate binding129,130. This relative burial of 
the active site as compared to caspases does not affect the enzyme efficiency.  HIV-1 
protease exhibits a higher turnover of 42.3 s-1 while caspases in general exhibit much 
slower turnover on the order of 1 s-1, even though the active site is much more exposed. 
However, the Km of the buried active site in HIV-1 is much lower (3.7 µM) as compared 
to caspases, which have Km constants on the order of 60-100 µM. One might assume that 
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the protein with more flexible loops would have a lower Km, as the active site binding 
groove is more flexible and thus less likely to hold substrate. However as we see in this 
example, this is not the case. The high Km may be related to the necessity for higher 
specificity in caspases, combined with the rearrangement of the loops between at least 
two states in solution.  
The discovery of the two distinct caspase-7 states in solution, as described earlier in the 
pistol metaphor, has wide ranging implications for the further use of caspases. Because 
the global folds of caspases are so similar, this lends credence to the idea that the two 
state nature of caspase-7 is not unique among caspases. Along these lines, the large 
thermal stability increase noted in caspases, in particular caspase-7, can be used in drug 
design efforts not currently being undertaken. Using methods like thermo sensitive dyes 
to detect thermal denaturation is established, and has been used in high throughput 
applications for drug discovery131. This method relies on a difference in Tm upon the 
binding of ligand to differentiate specific and non-specific binders. The noted changes in 
thermal stability upon binding of ligand vary in caspases. For instance, caspase-7 and 
caspase-9 share the highest known difference between bound and unbound states of 17 
degrees (Caspase-9 thermal melt data generously provided by Kristen Huber, 
unpublished). This is compared to caspase-3 which has a Tm of greater than 7 degrees, 
and -6, which has a %Tm of only 3 degrees27. The low %Tm for caspase-6 has can be 
explained in the appearance of an extended helix that preselects caspase-6 to a more 
active state, however the lower %Tm for caspase-3 relative to caspase-7 is likely due to the 
inability to measure melting temperatures above 90 degrees on the CD spectrometer used. 
The similar structures of other caspases suggest that a one would find increase of stability 
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on the order of 17 degrees upon binding substrate. The energy associated with binding 
and stabilization on this scale is not trivial. This stabilization in caspases can be 
compared to the binding of biotin to streptavidin, an incredibly tight interaction, which 
results in a thermal stabilization of 37 degrees in Tm 132. In the interaction of streptavidin 
to biotin130, the strong binding of the biotin to the hydrogen bonding network, Van der 
Waals surface burial and high shape complementarity all contribute to the strength of this 
non-covalent interaction.  
In the thermal denaturation studies of caspases to date, a covalent inhibitor has been 
present in the active site. The covalent nature of this interaction could affect the final 
active site binding groove arrangement, as these loops could relax and adopt a low energy 
state that is not necessarily biologically relevant. However, recent studies have shown 
that the structure of caspase-7 in the presence of a non-covalently bound inhibitor adopts 
a nearly identical conformation to that of the covalent inhibitor (structural information 
provided by Scott Eron, unpublished data). This strongly suggests that not only are the 
peptide-protein contacts sufficient to maintain caspase-7 in an active state, but that the 
covalent bond at the catalytic cysteine to the inhibitor is not the driving force behind the 
formation of the active site, but instead the peptide recognition is. From this, we expect 
that all caspases, when interacting with the target substrate during a recognition period, 
would adopt a conformation that is significantly stabilized. Thus, the native disulfide we 
observe in caspase-7 could be stabilizing a non-ideal substrate recognition motif in 
caspase-7, allowing the substrate to bind non-ideally, but still in a regime that allows for 
proteolysis.  
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Designing an inhibitor that targets the loop arrangement and not simply the binding 
pocket65, interrupting the formation of the loop bundle buttress can be an effective 
method for additional caspase control particularly when the loops can be accessed from 
outside the substrate binding groove.  Furthermore, the use of FRET as a measuring 
tool133 with labeled residues on L2 and L2’ or hydrogen-deuterium exchange would give 
additional insight to dynamic loop movement in solution not necessarily present in 
circular dichroism data alone. Structural information can significantly improve the ability 
to determine the importance of potential disulfide bridges. Stabilization of a particular 
conformation is a very common method of protein regulation or even activation. In the 
classic example of chymotrypsinogen, a pair of disulfide bridges stabilizes the active 
form of the enzyme after the cleavage of residues that active the protein. Design of a 
redox-controlled protein necessarily relies on the protein adopting a different 
conformation than the active, this can be done as in caspase-7 where the structure of a 
known inactive state exists. In the design of a of a redox controlled lysozyme, where only 
the active conformation was known, Matthews and colleagues engineered in a disulfide 
that deactivates the protein in the presence of a oxidizing environment134. The inherent 
flexibility of T4 lysozyme allowed the formation of a disulfide bridge that disabled the 
enzyme by locking the two lobes of the protein together. In our design of a redox-
controlled caspase, we used a known structure of caspase-7 in the allosterically inhibited 
form as a starting point. In the case of caspase-3, the lack of structural information of a 
L2’ loop down conformation precluded the initial structural study of a redox loop locked 
conformation, even when the native sequence of caspase-3 contains a homologous 
potential disulfide to R210C in caspase-7. We postulate that because of the structural 
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similarities within caspases, the design of redox loop locked caspases is not limited to 
caspases of which we have structures of multiple conformations such as caspase-7. 
Therefore, the application of a loop lock as we have designed can be integrated into not 
only caspase-3 and -7, but also into other caspases, which would be eminently useful to 
allosterically control. As has been previously shown135,136,109,137, delivery of active 
proteins into cells is possible. The possibility of delivering a functional caspase into cells 
with down regulated apoptosis using the redox-controlled method would allow direct and 
controlled initiation of apoptosis. Delivering caspases directly to where they are needed 
would be of great benefit for targeted cancer treatments, as minimization of off target 
effects would limit damage to surrounding tissue.  
Additionally, the capability to lock the loops over the caspase allosteric site allows less 
than optimal designs from computational binding site design to be studied 
crystallographically in the presence of the inhibitor. For instance, if the inhibitor has poor 
binding affinity for the new designed allosteric site, a designed caspase can be incubated 
in the presence of the non-covalent effector molecule in reducing conditions. The small 
molecule can then be ‘trapped’ by the locking of the L2’ loops over the allosteric cavity 
simply by the transference of the protein into an oxidizing environment.  
A design method of using computational protein redesign can be combined with methods 
currently underway in the Hardy lab, where specificity for substrate or allosteric sites are 
being altered. Using EGAD design techniques along with existing mutants and their 
effect on specificity, fewer new designs may have to be tested in the lab. Similarly, 
EGAD designs can be improved by the use of real specificity data being collected in the 
lab.  
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Data from the studies discussed in this thesis can be applied generally to other systems as 
demonstrated and discussed. The importance of the large rearrangement of the loop 
bundle during catalysis as discussed in chapter 2 has implications not only for 
computational redesign of the allosteric cavity (Chapter 4), and the design for redox 
control of caspase-7 (Chapter 3), but on designs of caspase specific inhibitors and further 
studies into the dynamics of caspases. To design inhibitors for a protein with large 
dynamic rearrangements, taking into account the loop rearrangement can be 
advantageous, as foreknowledge of sites not amenable to mutation, such as I213 on L2’, 
one can target it specifically.  
A direct application of the knowledge from the study of L2’ is a design of a redox 
activatable caspase-7 that makes proteins eminently more drug like, as these designed 
proteins can be delivered to systems with down regulated apoptosis (Chapter 3).  
The strength of the toolset lies in the execution, as EGAD demonstrates by utilizing the 
vast and inexpensive computational power available to test and therefore design a novel 
binding site that can function as an allosteric effector. The combination of a large 
sampling size of potential variants on the order of 1024 with multi-factored scoring 
(Chapter 4) can significantly decrease the wet lab experimental workload. Combined with 
the approaches outlined above, a new allosteric binding site can be engineered 
successfully. 
 It is the hope of the author that future investigators apply the lessons learned and data 
gathered to improve the impact of their experiments and science as a whole.  
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APPENDICIES 
A. CASPASE-7 IN THE PRESENCE OF AN UNCLEAVABLE PEPTIDE  
Abstract 
The ability to design individual caspase specific inhibitors is hindered by the shared 
specificity of the executioner caspases. However, it is clear from numerous studies that 
the in vivo targets of the executioner caspases vary. Thus, the understanding of the 
substrate-binding groove, and by extension substrate binding and proteolysis in 
particular, relies heavily on accurate atomic positioning of the catalytic residues. In this 
work we present a new approach to study protein function and geometry in the presence 
of an uncleavable substrate mimic, DEVD|GK. Crystallographic and binding evidence in 
the presence of DEVD|GK suggests an unexpected binding mode and overall caspase-7 
conformation not compatible with the canonical caspase-7 substrate-binding models, 
which all rely on covalent modification of the active-site cysteine by an electrophilic 
warhead on a peptide-derived inhibitor.  
Introduction 
Structures of caspase-7 have been solved numerous times in the presence of a covalently 
bound substrate in the active site37,61,88. However, in each of these structures with the 
catalytic cysteine bound to the peptide, the geometry of the cysteine-histidine dyad 
(C186, H144) is incompatible with catalysis. In every case, the cysteine’s gamma sulfur 
is at minimum 5Å from the histidine nitrogen. Similarly, in previously reported structures 
of caspase-7 with nothing bound to the active site39, the dyad is not in a catalytic 
orientation, being 4Å to 6Å apart. At the time this project was undertaken, 
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crystallographic data from the R210C/C246S caspase-7 variant was not yet obtained, and 
a structure of caspase-7 in the absence of an inhibitor but in a catalytic orientation was 
not available.   
To best determine the catalytic geometry of caspase-7 during catalysis, a structure of 
caspase-7 bound to an uncleavable substrate was desired. All commercially available 
active site inhibitors only included residues on the N-terminal side of the cleavage, so no 
information is available about binding of amino acids on the prime side of the binding 
groove. It was decided that introducing an uncleavable modified peptide bond between 
the naturally occurring cleavage site C-terminal to the aspartate and a subsequent residue 
would encourage substrate binding using the intrinsic binding sequence (DEVD) but 
disallow peptide bond cleavage and thus substrate release. Though caspase-3 and 
caspase-7 specificity has been extensively probed138,139 it has been conclusively shown 
that both proteins share a canonical recognition sequence (DEVD). Recent proteome 
wide substrate analysis of caspase-3 and caspase-7 show differences in P1’ and P2’ 
recognition sites. The potential additional benefit of mapping the P1’ and P2’ sites 
encouraged the use of a substrate sequence specific to caspase-7140. A sequence of DEVD 
linked by an uncleavable modified peptide bond to GK was selected for synthesis and 
analysis.  
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Figure 45: The uncleavable caspase-7 peptide DEVD|GK. 
A caspase-7 specific uncleavable peptide consisting of DEVD followed by a modified peptide bond 
lacking the carbonyl oxygen (red circle) links residues GK.   
The synthesis and chemical characterization of DEVD|GK was undertaken by Dr. 
Sumana Ghosh. Details can be found in the materials and methods of this chapter.  
Results 
Crystal structure of Caspase-7 with DEVD|GK 
After synthesis and characterization, the uncleavable peptide DEVD|GK was co-
crystallized with caspase-7 WT protein, and three independent data sets were obtained 
and solved. As the structure of caspase-7 with DEVD|GK was suspected to be most 
similar to the structure of caspase-7 in the presence of a covalently bound inhibitor, the 
model for molecular replacement was 1F1J with loops removed to minimize bias in the 
loops region. Initial observations of the maps from the molecular replacement solution 
suggested strongly that a new caspase-7 structure had been observed. When overlaid with 
1F1J, density for the loops L2, L3, and L4 were not in an identical conformation or not 
visible in density entirely. This fact was particularly surprising as all existing structures 
with substrate bound to the active site had nearly identical loop structures. Even in a 
structure of caspase-7 with severely impaired activity (see Chapter 2), the loops adopt a 
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conformation nearly identical to that of WT. Other minor changes across the whole 
protein were observed during rebuilding.  
Only one active site of C7 + DEVD|GK is ordered in the crystal structure. During 
rebuilding, repeated attempts were made to build in loops near the active site of chain A 
(one half of the dimer, composed of a large and small subunit), however, this was met 
with difficulty, as the density remained ambiguous and discontinuous. In contrast, the B 
chain of the protein not only had better density for the active site loops, but also 
contained density consistent with the binding of DEVD|GK in a similar motif to the 
binding of DEVD in 1F1J.  
 
Figure 46: Active site and DEVD visible in one half of dimer 
Density for the active site cysteine is only present on one side of the dimer (chain B). (A) Density 
for the uncleavable peptide is visible for residues DEV (magenta), but is discontinuous and 
ambiguous further.  (B) The uncleavable peptide (magenta) adopts a conformation that is related to, 
but not identical to the active site bound peptide in 1F1J (cyan).   
Attempts to improve density throughout the protein, non-crystallographic symmetry 
(NCS) across the whole dimer was applied to a refinement step. After this containment 
was applied, overall refinement statistics did not improve, rather got worse, suggesting 
that the two halves of the protein could not be treated identically. NCS was successfully 
C186 
B A 
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applied to improve refinement statistics in regions of caspase-7 that did not vary from 
each side. Specifically, the "-sheet regions that form the core of caspases were used. 
Residues 66-73, 136-141, 176-186, and 218-233 held with tight restraints at the backbone 
position and medium restraint for the side chains.   
Disulfide visible on one side of caspase-7 dimer 
Although the binding of the peptide at the active site is somewhat ambiguous, the 
discovery of disulfide bond formation at residues C100 and C246, between the large and 
small subunits (Figure 19, Chapter 3) is of great interest. Intriguingly, this disulfide was 
only visible on one side of the dimer, opposite of the side that showed good density for 
the active site. A map generated with the residues C100 and C246 omitted shows clear 
and unambiguous contiguous density consistent with a disulfide formation (Figure 47 A). 
However, the same is not the case on the opposite side of the dimer, where the density for 
disulfide formation is not evident (Figure 47 B).  
 
Figure 47: Native C100-C246 disulfide visible in omit map 
The formed disulfide is clearly visible on one side of the dimer in a map generated with residues 
C100 and C246 omitted. (A) Both the Fo-Fc density (green, 3) contouring) and 2Fo-Fc (blue, 1) 
contouring) is continuous at the site of the omitted C100-C246. (B) On the opposite side of the 
dimer, the density rendered identically is discontinuous, and does not show evidence of disulfide 
formation. 
B A 
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We confirmed these results in three independent data sets, each collected on an 
independent crystal.  
 
C7 + DEVD|GK 
 
Data Set 1 
 
Data Set 2 
 
Data Set 3 
 
 
Diffraction Data 
      
  
Wavelength (Å) 
 
1.00 
 
1.00 
 
1.00 
  
Resolution Range  (Å) 
 
50-2.75 
 
50-2.80 
 
50-2.9 
  
Measured reflection 245450 
 
298058 
 
82617 
  
Unique reflections 
 
23376 
 
22243 
 
19670 
  
Completeness (%) 
 
99.9 (100) 
 
100 (100) 
 
99.4 (99.7) 
  
Redundancy 
 
10.5 (10.6) 
 
13.4 (13.4) 
 
4.2 (4.2) 
  
<I/!I> 
 
38.9 (2.1) 
 
36.0 (2.1) 
 
24.6 (2.2) 
  
Space Group 
 
P3221 
 
P3221 
 
P3221 
  
a = b (Å) 
 
90.028 
 
90.014 
 
90.016 
  
c (Å) 
 
185.261 
 
185.645 
 
185.702 
  
# = " (°) 
 
90 
 
90 
 
90 
  
' (°) 
 
120 
 
120 
 
120 
  rsym  7.3 (99.7)  10.4 (89.0)  8.2 (55.6) 
         
 
Refinement Statistics 
      
  
Atoms 
 
3486 
    
  
Water molecules 
 
25 
    
  
Rwork (%) 
 
29.6 
    
  
Rfree (%) 
 
23.2 
    
  
RMSD bond length (Å) 
 
0.021 
    
  
RMSD bond angle (°) 
 
2.15 
    
  
Average B-factor (Å2) 
 
58.3 
     
Table 7: Crystallographic statistics for three independent datasets of caspase-7 with DEVD|GK 
Data sets are stored on the Hardy linux workstation, solitude, in the /home/xray_data/X25 Aug 
2010/px10-0295 directory. Data set 1 is stored in the subdirectory /W2_UK_3/5 Data set 2 in 
/C7_DEVDGK_1_8/ and Data set 3 in /C7_DEVDGK_2_1/ 
Inhibition of caspase-7 using DEVD and DEVD|GK 
In light of the unusual structural results of caspase-7 co-crystallized with DEVD|GK, 
binding of DEVD|GK vs DEVD was compared. To asses whether DEVD|GK binds in 
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similar fashion to the native recognition sequence of DEVD, DEVD|GK’s inhibition was 
compared to the peptide DEVD. It was expected that the recognition sequence of 
DEVD|GK would be sufficiently similar to that of DEVD, causing the inhibition to be 
similar to product inhibition, and be competitive.  
 
Figure 48: Inhibition curves based on substrate titration 
The inhibition titration curves of DEVD (A) vs DEVD|GK (B) measured during a substrate titration 
using DEVD-AMC as substrate with protein concentrations of 250 nM for DEVD 175 nM for 
DEVD|GK.  
 
 
0 µM  
 
200 µM 
 
400 µM 
 
DEVD 
 
DEVD|GK 
 
DEVD 
 
DEVD|GK 
 
DEVD 
 
DEVD|GK 
kcat  217.2  225.2  73.9  179.6  36.0  150.0 
Km 65.3 
 
45.93 
 
95.86 
 
47.8 
 
235.1 
 
46.04 
                       
Table 8: Kinetic parameters of caspase-7 in the presence of DEVD and DEVD|GK.  
Kinetic parameters are fit from data in Figure 48.  
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Discussion 
The surprising results from the crystal structure, and the unexpected inhibition results 
suggest a different binding mode for the un-cleavable peptide. In the crystal structure, the 
peptide is visible to the P2 position, however the density becomes ambiguous and non-
contiguous making the placement of the P1 aspartate impossible. Similarly, the P1 pocket 
is occupied by the catalytic cysteine where in the 1F1J structure the P1 aspartate finds the 
P1 site (Figure 46).  Then minor but significant differences between the 1F1J structure 
and the structure with the un-cleavable peptide around the active site suggest that 
DEVD|GK does not bind in the canonically understood fashion.  
It is also significant that there are obvious differences between the two halves of the 
dimer. While the uncleavable peptide can be resolved on one half of the dimer, the 
opposite side of the dimer is much more disordered. The region surrounding the active 
site in chain A is missing many more residues. Specifically, the catalytic cysteine in chain 
A is not visible nor is the uncleavable peptide. 
This asymmetry is carried forward in the region of the C100-C246 disulfide. 
Interestingly, the disulfide is visible only on the side of the dimer where the active site is 
disordered. On the side of the diner where peptide is visible, the disulfide is clearly not 
formed (Figure 47). The cause of this asymmetry may be related to the unexpected 
binding mode of the uncleavable peptide. The uncleavable peptide is not acting like a 
competitive inhibitor to the fluorescent substrate, rather it is only affecting the kcat, while 
leaving KM unaffected thus exhibiting classic noncompetitive inhibition properties. On 
the other hand, the control DEVD peptide, is exhibiting mixed inhibition in that both KM 
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and kcat are being affected.  It is therefore difficult to conclude with any certainty on the 
mechanism of binding or inhibition despite the solution of a crystal structure.  
Although the kinetics experiments leave much to be studied, the crystallographic data is 
more conducive of interpretation.  The appearance of resolvable uncleavable peptide on 
one half of the dimer, while a stabilizing disulfide is formed on the opposite side of the 
dimer may suggest that caspase-7 can accommodate binding of substrates in odd 
confirmations. The uncleavable peptide necessarily contains a non-natural peptide bond 
right at the site of caspase-7 cleavage between D and G in DEVDGK. This un-cleavable 
bond has sp3 geometry as opposed to the standard peptide bond sp2 geometry. One 
additional conclusion that can be made from the crystallographic data is that the 
treatment of caspase-7 as a set of identical monomers is not valid. The imposition of non-
crystallographic symmetry during structural refinement must be made judiciously, as the 
dimers appear to act independently.  
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Materials and Methods 
Synthesis of uncleavable bond peptide 
The synthesis and characterization of the uncleavable DEVD|GK peptide was done by 
Dr. Sumana Ghosh during her tenure in the Hardy Lab. Figure used with permission.  
 
 
Fmoc-L-Asp-N(Me)OMe,(9H-fluoren-9-yl)methyl-(S)-1-(N-methoxy-N-
methylcarbonyl)-2 (tert-butoxycarbonyl)ethylcarbamate, (3). N-Fmoc-L-aspartic acid "-
tert-butyl ester  (2, 2 gm, 4.86 mmol) and N,O-dimethyl hydroxylamine hydrochloride 
!
!
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(0.57 gm, 5.83 mmol) were dissolved in 15 ml DMF. The reaction mixture was cooled 
and DIEA (2 ml, 11.7 mmol) followed by HBTU (2.2 gm, 5.83 mmol) were added into it.  
The resulting solution was allowed to stir for 5-6 h at room temperature. At end the 
reaction mixture was extracted with ethylacetate and successively washed with 0.2 N 
HCl, saturated NaHCO3 solution and finally with brine. The crude gummy liquid was 
purified by column chromatography using 0.5 % MeOH/DCM as the eluent. The solvent 
was evaporated to afford gummy liquid (3, 1.7 gm) as 80% isolated yield. 1H-NMR 
(CDCl3, 400 MHz) * (ppm) 1.44 (s, 9H), 2.6 (dd, J1 = 16 Hz, J2 = 7 Hz, 1H), 2.74 (dd, 
J1 = 16 Hz, J2 = 5.3 Hz, 1H), 3.2 (s, 3H), 3.8 (s, 3H), 4.23 (t, J = 7.1 Hz, 2H), 4.36 (d, J = 
7.3 Hz, 2H), 5.04 (m, 1H), 5.72 (d, 1H), 7.32 (t, J = 7.4 Hz, 2H), 7.4 (t, J = 7.4 Hz, 2H), 
7.6 (d, J = 7.4 Hz, 2H), 7.76 (d, J = 7.5 Hz, 2H). (Lab Note book, p. 94, 98) 
 (9H-fluoren-9-yl)methyl-(S)-2-(tert-butoxycarbonyl)-1-formylethylcarbamate,(4). To a 
solution of Weinreb amide (3, 0.1 gm, 0.22 mmol) in 2 ml anhydrous THF, 13 mg (0.33 
mmol) Lithium aluminium hydride was added at 0 oC (ice).  The reaction mixture was 
stirred at 0 oC for 2 h 30 min. and then quenched by addition of 10 ml 5% KHSO4 
solution. The resulting solution was extracted with ethylacetate, washed 2 or 3 times with 
5 % KHSO4 solution, brine and dried (MgSO4) and concentrated under reduced pressure. 
The resulting aldehyde was purified by silica column chromatography eluting with DCM 
and MeOH/DCM mixture. The final compound was obtained using 2-2.5 % MeOH/DCM 
as eluent . The aldehyde was obtained as gummy liquid almost 70 % (0.06 gm) isolated 
yield. 1H-NMR (CDCl3, 400 MHz) * (ppm) 1.45 (s, 9H), 2.78 (dd, J1 = 17.2 Hz, J2 = 4.6 
Hz, 1H), 2.96 (dd, J1 = 17.2 Hz, J2 = 4.8 Hz, 1H), 4.24 (t, J = 6.8 Hz, 2H), 4.38-4.46 (m, 
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3H), 5.9 (d, 1H), 7.32 (t, J = 7.4 Hz, 2H), 7.4 (t, J = 7.5 Hz, 2H), 7.6 (d, J = 7.4 Hz, 2H), 
7.77 (d, J = 7.5 Hz, 2H) 9.65 (s, 1H).  
 
(9H-fluoren-9-yl)methyl(S)-1-(((benzyloxy)carbonyl)methylamino)-3-(tert-
butoxycarbonyl) propan-2-ylcarbamate, (5). Compound 4 (1.1 gm, 2.8 mmol) was 
dissolved in 7 ml MeOH. Into that p-toluenesulfonate salt of Gly-OBn (1.13 gm, 3.36 
mmol) along with 0.208 ml (3.64 mmol) acetic acid and some amount of molecular 
sieves were added. The resultant mixture was stirred at room temperature for an hour. 
Then sodium cyanoborohydride (3.36 mmol, 0.25 gm equivalent to 4 ml of 1 M 
NaCNBH4 solution in THF) was added dropwise into the reaction mixture at room 
temperature. Immediately a white precipitate starts forming and continued stirring at 
room temperature for overnight. The resultant solution was then diluted with methanol, 
filtered and evaporated. The resultant crude compound was dissolved in ethylacetate and 
successively washed with water, saturated NaHCO3 solution, brine and dried over 
Na2SO4. The product was purified using EtOAC/Hexane as eluent and the product was 
obtained using 20% ethylacetate/hexane as eluent. 1H-NMR (CDCl3, 400 MHz) * (ppm) 
1.45 (s, 9H), 2.51 (dd, 1H), 2.54 (dd, 1H), 2.76 (dd, 1H), 2.82 (dd, 1H), 3.47 (d, J = 6.0 
Hz, 2H), 4.05 (m, 1H), 4.23 (t, J = 7 Hz, 2H), 4.4 (d, J = 6.6 Hz, 2H), 5.2 (s, 2H), 5.6 (d, 
1H), 7.3-7.4 (m, 9H), 7.6 (d, J = 7.4 Hz, 2H), 7.76 (d, J = 7.5 Hz, 2H).  
Synthesis of (6). Compound 5 (0.22 gm, 0.4 mmol) was dissolved in 10 ml anhydrous 
THF followed by the addition of 14 µl (0.08 mmol) DIEA. The reaction mixture was 
cooled to 0oC and BOC2O(DiBoc Anhydride) (0.096 gm, 0.44 mmol) was added 
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dropwise into it. The resultant solution was stirred at room temperature for 6 h. The 
solvent was evaporated and purified by silica column chromatography. The product was 
obtained while eluting with 1% MeOH/DCM for an 80% (0.17 gm) isolated yield. 1H-
NMR (CDCl3, 400 MHz) * (ppm) 1.42 (bs, 18H), 2.47 (dd, J1 = 17.0 Hz, J2 = 6.4 Hz, 
1H), 2.62 (dd, J1 = 14.0 Hz, J2 = 5.1 Hz, 1H), 3.3-3.4 (m, 1H), 3.5-3.62 (m, 1H), 3.96 (q, 
J1 = 12.0 Hz, 2H), 4.03-4.05 (m, 1H), 4.2 (t, J = 7 Hz, 2H), 4.35 (dd, J1 = 25.4 Hz, J1 = 
5.6 Hz, 2H), 5.2 (s, 2H), 5.6 (d, 1H), 7.3-7.4 (m, 9H), 7.6 (d, J = 7.4 Hz, 2H), 7.74 (d, J = 
7.5 Hz, 2H).  
Synthesis of (1). Compound 6 (1.2 gm, 1.86 mmol) was dissolved in 20 ml MeOH and 
Pd/C (Paladium charcoal) (10%, 150 mg) was added into it under inert atmosphere. The 
reaction mixture was stirred and hydrogenated over 2h 30 min. The resultant solution was 
filtered and purified by silica column chromatography. The product was obtained while 
eluting with 2% MeOH/DCM mixture. The yield of the reaction is almost 85%. 1H-NMR 
(CDCl3, 400 MHz) * (ppm) 1.42 (bs, 18H), 2.45-2.5 (dd, J1 = 17.0 Hz, J2 = 6.4 Hz, 1H), 
2.59-2.64 (dd, J1 = 14.0 Hz, J2 = 5.1 Hz, 1H), 3.3-3.4 (m, 1H), 3.51-3.62 (m, 1H), 3.94 
(q, J1 = 18.0 Hz, 2H), 4.03-4.05 (m, 1H), 4.2 (t, J = 7 Hz, 2H), 4.35 (dd, J1 = 25.4 Hz, J1 
= 7 Hz, 2H), 5.97 (d, 1H), 7.3 (t, J = 7.4 Hz, 2H), 7.38 (t, J = 7.4 Hz, 2H), 7.6 (m, 2H), 
7.74 (d, J = 7.5 Hz, 1H)  
 
Inhibition assays with DEVD and DEVD|GK 
Enzyme concentrations were determined by active site titration with covalent substrate 
DEVD-CHO (N-Acetyl-Asp-Glu-Val-Asp-Aldehyde, Enzo Lifesciences) in caspase 
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activity buffer containing 100 mM HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid) pH 7.0, 10% polyethylene glycol 400, 0.1% CHAPS, 5 
mM "-mercaptoethanol, and 5 mM CaCl2 using the flourogenic substrate, DEVD-AMC 
(N-acetyl-Asp-Glu-Val-Asp (7-amino-4-methylcoumarin), Enzo Lifesciences), 
Ex365/Em495.  Active site titration samples were incubated over a period of 2 hours in 
120 mM NaCl 20 mM Tris pH 8.0 at nanomolar concentrations.  Optimal labeling was 
observed when protein was added to DEVD-CHO solvated in DMSO in 96-well V-
bottom plates, sealed with tape, and incubated at room temperature.  22.5 µL and 90 µL 
aliquots were transferred to black-well plates in duplicate, and assayed with 50-fold 
molar excess of substrate. For substrate inhibition measurements, 100 nM protein was 
assayed with DEVD (Biomatic Corporation) or DEVD|GK (synthesized in house by Dr. 
Sumana Ghosh) present using a fluorescent substrate titration over the range of 0-1000 
µM DEVD-AMC over the course of seven minutes. Data for concentrations above 1000 
µM was omitted due to observed product inhibition. Assays were performed at 37°C in 
25 µL and 100 µL volumes in 96 or 384 well microplate format using a Molecular 
Devices Spectramax M5 spectrophotometer. Initial velocities versus substrate 
concentration were fit using Prism software (Graphpad Software) to determine 
parameters Km, KIapp and kcat.   
Caspase-7 + DEVD|GK crystallization and x-ray data collection 
To prepare caspase-7 with DEVD|GK crystals, protein in a buffer containing 120 mM 
NaCl and 20 mM Tris pH 8.0 was concentrated using Millipore Ultrafree 5K NMWL 
membrane concentrators (Millipore) to 7.8 mg/mL as assessed by absorbance at 280 nm. 
DEVD|GK peptide dissolved in water was added in 4 fold molar excess and incubated for 
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one hour. Crystal trays were setup at room temperature and grown in 3.5 µL hanging drop 
with mother liquor consisting of 100 mM citrate buffer, 1M LiSO4 1M NaCl in a 2.5:1 
ratio of protein to mother liquor. Crystals grew to a maximum of 250 µm in 7 days at 20 
degrees. Crystals were cryoprotected in 20% ethylene glycol in mother liquor with a 60 
second incubation, then frozen by rapid immersion in liquid N2. Data were collected 
using synchrotron radiation at Brookhaven X25 over 300 frames with 1° oscillations and 
showed diffraction data to 2.75Å, with frames 1-50, 142, and 175-245 omitted for data 
set 1. Data set 2 was collected identically over 275 frames, with frames 105-145 omitted. 
Omitted frames were due to high linear R-factor. Data set 3 was collected identically to 
data sets 1 and 2 over 70 frames. Indexing, integration and scaling were carried out with 
HKL200073. Data for the lower resolution crystals were collected during the same data 
collection trip. 
Structure determination 
Phase information was obtained by molecular replacement using 1F1J as the search 
model with residues corresponding to L2' omitted during searches with PHASER115. 
Removed residues were rebuilt into unambiguous density using COOT116, then refined 
using Refmac117 restrained refinement with TLS enabled and NCS applied to residues 66-
73, 136-141, 176-186, 233-218. Water and sulfate molecules were inserted manually and 
checked for stereochemical appropriateness. The final refined model from data set 1 
contains residues 55–185, 214–226, 236–304 for chain A and 54–188, 212– 306 for chain 
B. Uncleavable peptide is modeled for residues DEV as chain E, 25 water molecules are 
assigned chain O, and 2 sulfates assigned chain S. 
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B: EGAD SCRIPTS 
Outputs and tabulated output data in excel format can be found on the Hardy linux 
workstation solitude in the /home/shared/EGAD directory.  
1SHJ_A.input 
START 
 
#### Input files #### 
# Each of these lines declares the location of an input file 
# for the design calculation. 
 
# The PDB file that serves as the template for this monomer 
TEMPLATE_PDB     
/mnt/nmr2/people/witold/Hardy_collab/C7_Tet_1.0/1SHJ_A.pdb 
 
# The resparam file that defines prototype residues 
RESPARAM_FILE     
/mnt/nmr2/people/witold/Hardy_collab/C7_Tet_1.0/common_inputs/vdw0.90.r
esparam 
 
# The forecfield file that defines atom-specific information, 
# such as VDW radii 
FORCEFIELD        
/mnt/nmr2/people/witold/Hardy_collab/C7_Tet_1.0/common_inputs/atoms.for
cefield 
 
# The rotamer file that defines the rotamer library 
ROTAMER_LIBRARY   
/mnt/nmr2/people/witold/Hardy_collab/C7_Tet_1.0/common_inputs/bbind02_m
ay.rotamers 
 
# The torsion parameter file that defines the torsional correction 
# for 1,4 bonded atoms 
TORSION_FILE      
/mnt/nmr2/people/witold/Hardy_collab/C7_Tet_1.0/common_inputs/opls.tors
ions 
 
# The SASA points file that defines test points on the unit sphere 
# for calculation of SASA. 
SASA_POINTS_FILE  
/mnt/nmr2/people/witold/Hardy_collab/C7_Tet_1.0/common_inputs/sasa.txt 
 
 
#### Energy table file settings #### 
# These two parameters instruct the application where to find 
# pre-calculated energy tables, and whether to load them or calculate 
# them fresh. Calculating fresh tables is recommended, in general. 
ENERGY_TABLE
 /mnt/nmr2/people/witold/Hardy_collab/C7_Tet_1.0/tet_caspase 
LOAD_ENERGIES 0 
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#### Variable position definitions #### 
# This section defines which positions will be allowed to mutate 
# during the design calculation. Its a simple table of position indices 
# (from the PDB file) and the residues allowed at that position. 
# 
# Any positions not mentioned here are assumed to be "fixed", that is 
# to say they will not move during a design. Any positions defined to 
# be the same as their wild-type counterpart will be allowed to change 
# rotamers. 
# 
# The special keyword "all" will allow any residue type (except GLY, 
# CYS, and PRO). 
VARIABLE_POSITIONS 
    159         all  # ILE 
    211         all  # Tyr 
    213         all  # Ile 
    221         all  # PHE 
    223         TYR  # ONLY ROTOMER CHANGE 
    290         all  # CYS 
    292         all  # VAL 
END 
 
#### Energy function settings #### 
# Each of these flags sets whether a portion of the energy function 
# should be used in the design calculation. A '1' means that it will 
# be included, while a '0' means it will not. 
VDW_FLAG          1 
COULOMB_FLAG      1 
TORSION_FLAG      1 
SASA_FLAG         1 
GB_FLAG           1 
HBOND_FLAG        0 
REFERENCE_FLAG    1 
 
#### Energy function parameters #### 
# Various parameters that modify how the energy functions behave. 
# At this point, I just use this to define what scaling factor to 
# apply to the VDW radius. 
VDW_RADII_SCALE 0.90 
 
END 
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1SHJ_B.input 
START 
 
TEMPLATE_PDB      
/mnt/nmr2/people/witold/Hardy_collab/C7_Tet_1.0/1SHJ_B.pdb 
 
VARIABLE_POSITIONS 
    159         all  # ILE 
    211         all  # Tyr 
    213         all  # Ile 
    221         all  # PHE 
    223         TYR  # ONLY ROTOMER CHANGE 
    290         all  # CYS 
    292         all  # VAL 
END 
 
END 
 
Dox.liginput 
START 
 
PARAMETER_FILE  dox.ligparam 
LOCATION 
    COORDINATES         53.538    13.249     3.811 
    SPREAD_RADIUS       2.0 
    SPREAD_GRAIN        3.0 
    XYZ_ROTS  3 3 3 
    XYZ_RANGE           0.195 0.195 0.195  
END_LOCATION 
 
END 
 
Dox.ligparm 
EGAD Ligand Parameter file for Doxycycline 
by Arnab Chowdry; edited by Witold Witkowski 
8-14-2007 
 
Format Key: 
  Each LIGAND entry holds the information necessary to define one 
ligand. 
 
  CORD lines hold atom coordinate information: 
        Atom Number Atom Name   Atom Type  Rigid Body     x       y       
z    Charge 
  CORD       1          CA          CT         3        2.340   1.155  
10.616  0.000 
 
  CNCT lines hold atom connectivity information, expressed as a list of 
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       atoms directly connected to the first one: 
        Parent Atom     Bonded Atoms 
  CNCT       1            2 4 5 6 
 
  ROTB lines hold rotable bond information. Atoms connected to the 
first atom (excluding the second atom) will be dependent on the rotable 
bond: 
        First Atom  Second Atom 
  ROTB       
START 
LIGAND DOX 
CORD 1 C CA 0   52.569  15.775   3.409    0.084104 
CORD 2 C CA 0   53.435  16.652   2.849    0.434036 
CORD 3 C CA 0   54.774  16.229   3.364    0.007574 
CORD 4 C CA 0   54.924  14.645   3.172    0.060912 
CORD 5 C CA 0   53.683  13.942   2.473    0.672938 
CORD 6 C CA 0   52.192  14.519   2.676     -1.551142 
CORD 7 C CA 0   53.795  12.445   2.762     -1.127784 
CORD 8 C CA 0   53.736  12.115   4.245     -0.567027 
CORD 9 C CA 0   54.748  12.933   5.031     0.853653 
CORD 10 C CA 0   55.347  14.009   4.492     0.212514 
CORD 11 C CA 0   55.006  12.507   6.420    0.493023 
CORD 12 C CA 0   54.390  11.248   6.895    0.557629 
CORD 13 C CA 0   53.832  10.334   5.986   -0.23334 
CORD 14 C CA 0   53.943  10.603   4.502   -0.57567 
CORD 15 C CA 0   53.224   9.178   6.445    -0.333433 
CORD 16 C CA 0   53.173   8.912   7.812    -0.409527 
CORD 17 C CA 0   53.732   9.788   8.720    -0.022899 
CORD 18 C CA 0   54.348  10.950   8.269    -0.073312 
CORD 19 C CH3 0   50.154  15.356   1.682    -0.405255 
CORD 20 C CN 0   53.503  16.985   1.411    0.573606 
CORD 21 C CH3 0   51.536  13.926   0.302   -0.200686 
CORD 22 C CH3 0   55.273  10.044   3.956   -0.758613 
CORD 23 H HA 0   53.713   9.601   9.774    0.264047 
CORD 24 H HO 0   55.356  12.506   8.863    0.584718 
CORD 25 H HO 0   52.964  11.257   1.338   0.499983 
CORD 26 H HC 0   52.545  13.671   0.028   0.176319 
CORD 27 H HC 0   51.097  14.439  -0.543   0.194366 
CORD 28 H HC 0   50.980  13.010   0.486    0.202262 
CORD 29 H HC 0   49.764  15.781   0.768    0.193855 
CORD 30 H HC 0   49.470  14.575   2.019    0.180426 
CORD 31 H HC 0   50.173  16.138   2.430    0.446138 
CORD 32 H HN 0   51.968  18.326   1.517   0.291143 
CORD 33 H HA 0   53.882  14.106   1.427    0.243309 
CORD 34 H HA 0   51.607  13.843   3.297   0.266719 
CORD 35 H HA 0   54.743  12.117   2.358    0.246798 
CORD 36 H HA 0   52.723  12.328   4.589   0.255958 
CORD 37 H HA 0   53.130  10.087   4.007   0.239156 
CORD 38 H HA 0   52.795   8.485   5.745    0.241564 
CORD 39 H HA 0   52.698   8.017   8.163    0.433676 
CORD 40 H HN 0   52.664  18.115  -0.034    0.554144 
CORD 41 H HO 0   52.374  14.855   5.164   0.569422 
CORD 42 H HO 0   56.723  15.392   4.666   0.212854 
CORD 43 H HC 0   55.387   9.012   4.261   0.225906 
CORD 44 H HC 0   56.126  10.599   4.327   0.173835 
CORD 45 H HC 0   55.301  10.066   2.873   0.542809 
CORD 46 H HO 0   56.012  15.052   1.540    0.447089 
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CORD 47 N N 0   51.503  14.842   1.440    -0.873187 
CORD 48 N N 0   52.619  17.869   0.928    -0.51929 
CORD 49 O OH 0   52.741  15.627   4.741   -0.591843 
CORD 50 O OH 0   56.387  14.606   5.091   -0.5372 
CORD 51 O OH 0   56.045  14.464   2.297   0.201514 
CORD 52 O O 0   55.639  13.205   7.222    -0.611946 
CORD 53 O OH 0   54.879  11.754   9.222    -0.765921 
CORD 54 O OH 0   52.718  11.745   2.115   -0.553176 
CORD 55 O O 0   54.419  16.517   0.708   -0.625366 
CORD 56 O O 0   55.718  16.888   3.715   -0.501389 
CNCT   1    2    6   49   
CNCT   2    1    3   20   
CNCT   3    2    4   56   
CNCT   4    3    5   10   51       
CNCT   5    4    6    7   33       
CNCT   6    1    5   34   47       
CNCT   7    5    8   35   54       
CNCT   8    7    9   14   36        
CNCT   9    8   10   11   
CNCT  10    4    9   50   
CNCT  11    9   12   52   
CNCT  12   11   13   18   
CNCT  13   12   14   15   
CNCT  14    8   13   22   37   
CNCT  15   13   16   38   
CNCT  16   15   17   39   
CNCT  17   16   18   23   
CNCT  18   12   17   53   
CNCT  19   29   30   31   47        
CNCT  20    2   48   55   
CNCT  21   26   27   28   47        
CNCT  22   14   43   44   45        
CNCT  23   17 
CNCT  24   53 
CNCT  25   54 
CNCT  26   21 
CNCT  27   21 
CNCT  28   21 
CNCT  29   19 
CNCT  30   19 
CNCT  31   19 
CNCT  32   48 
CNCT  33    5 
CNCT  34    6 
CNCT  35    7 
CNCT  36    8 
CNCT  37   14 
CNCT  38   15 
CNCT  39   16 
CNCT  40   48 
CNCT  41   49 
CNCT  42   50 
CNCT  43   22 
CNCT  44   22 
CNCT  45   22 
CNCT  46   51 
CNCT  47    6   19   21   
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CNCT  48   20   32   40   
CNCT  49    1   41 
CNCT  50   10   42 
CNCT  51    4   46 
CNCT  52   11 
CNCT  53   18   24 
CNCT  54    7   25 
CNCT  55   20 
CNCT  56    3 
done 
STOP 
 
 
Etable.cmdline 
allow-wt 
egad-input 1SHJ_A.input,1SHJ_B.input 
ligand-inputs dox.liginput 
 
Machines 
michael:2 
gabriel:2 
raphael:2 
uziel:2 
sariel:2 
Monte_carlo.cmdline 
random-seed 116200268 
num-runs 100000 
num-saved 1000 
num-steps 10000 
etable dox_caspase.etable 
groups dox_caspase.groups 
Montecarlo.sc 
#!/bin/bash 
# Monte Carlo Minimizer Script, by Witold 
 
echo "Running Minimizer" 
echo "Monte Carlo Simulation" 
echo monte_carlo.cmdline 
mpirun -all-cpus -machinefile machines ~/EGAD_Clients/bin/MPIMonteCarlo 
--CLPLoad=monte_carlo.cmdline &> monte_carlo.log & 
 
echo "The script should be running, checking monte_carlo.log for 
results" 
echo "Push CTRL+C to quit log file" 
tail -f monte_carlo.log 
Movestuff.sc 
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#This copies the important files to a new dir. 
#Edit the last bit!!!!! 
#Written by Witold, 6-6-07 
 
cp -r ./common_inputs 1SHJ_* dox.* machines *.cmdline *.py *.sc *.pdb 
*.pml ../doxdes3.2.27 
# rm solu*.* 
echo "That Should do it!" 
echo "Now remember to edit this file before you run it again!" 
Presurf.sc 
clear 
echo -e "         \E[5mI'm about to delete all the previous surfnet 
files\E[25m" 
echo "                          Push control-c to stop me!" 
sleep 1 
echo "5" 
sleep 1 
echo "4" 
sleep 1 
echo "3" 
sleep 1 
echo "2" 
sleep 1 
echo "1" 
rm *.srf 
rm *.grf 
rm surfnet.ps 
rm gaps* 
rm volumes* 
rm *.out 
clear 
echo -e "                                \E[5mRunning Surfnet...\E[25m" 
surfnet &> surfnet.out 
sleep 7 
surface &> surface.out 
sleep 5 
surfplot &> surfplot.out 
sleep 10 
clear 
echo "                                          All done" 
Print_structuresnue.py 
#!/usr/bin/python 
# 
# This script parses out the result data from a run of MPIMonteCarlo 
# and generates command lines for use with MPIPolymerTable. It has 
# been modified from previous versions to accept two lists of input 
# files: one for proteins and another for ligands. 
# 
# It also searches for duplicate solutions and removes them from the 
# output. 
# 
import re,sys,os 
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if (len(sys.argv) < 3): 
    print "Please specify a data file to process and associated input 
files." 
    sys.exit(1) 
# Maps sequence data to energy 
SOLUTIONS = {} 
# Maps energy value to 3-letter code sequence 
ENERGY_TO_SEQ = {} 
# The first file on the command line is an output file from a run of 
# MPIMonteCarlo, and should contain result lines that we need to parse 
# and store. 
find_data = re.compile("^OUTPUT:\s+\[[\d]+\][\s]+([\d\-
\.]+)\s+((?:[\d]+\.)+)") 
find_seq = re.compile("^OUTPUT:\s+\[[\d]+\][\s]+([\d\-\.]+)\s+((?:[A-
Z]{3}\.)+)") 
find_point = re.compile("^ENERGY:\s+([a-zA-Z\s]*) Point Energy is 
([\d\-\.]+)") 
fp = open(sys.argv[1],'r') 
for line in fp.readlines(): 
    match = find_data.match(line) 
    if match: 
        SOLUTIONS[match.group(2).replace('.',',')] = 
float(match.group(1)) 
    else: 
        match = find_seq.match(line) 
        if match: 
            ENERGY_TO_SEQ[float(match.group(1))] = match.group(2) 
fp.close() 
# Now we want to sort by energy value. To do this, we reverse the 
dictionary 
# into a sorted array. 
sorted = [(v,k) for k,v in SOLUTIONS.items()] 
sorted.sort() 
# Open a file to print summary data for the structures generated. 
fp = open("print_summary.txt",'w') 
i = 0 
energy_cats = {} 
energy_keys = [] 
for energy,sol in sorted: 
    command = "MPIPolymerTable -i " + sys.argv[2] + " -w -p" 
    sol = sol[:-1] 
    if (len(sys.argv) > 3): 
        command += " -l " + sys.argv[3] 
    else:  
 split_string = sol.split(",") 
 sol = ",".join(split_string[:-1]) 
    command += " -c " + sol + " -o solution_" + str(i) + ".pdb" 
    output = os.popen(command, 'r') 
    for line in output.readlines(): 
        match = find_point.match(line) 
        if match: 
            energy_cats[match.group(1)] = match.group(2) 
    if i == 0: 
        # Print headers 
        fp.write("SOLUTION\tENERGY\tSEQUENCE") 
        energy_keys = energy_cats.keys() 
        for key in energy_keys: 
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            fp.write("\t"+key) 
        fp.write("\n") 
    fp.write("solution_" + str(i) + 
":\t"+str(energy)+"\t"+ENERGY_TO_SEQ[energy]) 
    for key in energy_keys: 
        fp.write("\t"+energy_cats[key]) 
        energy_cats[key] = "N/A" # reset for next round 
    fp.write("\n") 
    i += 1 
    if i == 100: break 
# Close the summary file 
fp.close() 
Struct.sc 
#!/bin/bash 
# Structure Compilation script, By Witold (edited for +/- ligand 5-16-
08) 
# Uses the pthyon script, print_structures.py 
 
echo "Finding Structures!" 
python print_structuresnue.py monte_carlo.log 1SHJ_A.input,1SHJ_B.input 
echo "Renaming output file to summary_-_ligand.txt" 
mv print_summary.txt summary_-_ligand.txt 
python print_structuresnue.py monte_carlo.log 1SHJ_A.input,1SHJ_B.input 
dox.liginput 
echo "Renaming output file to summary_+_ligand.txt" 
mv print_summary.txt summary_+_ligand.txt 
echo "DONE" 
Tabling.sc 
#!/bin/bash 
# Tabling Script, by Witold 
 
rm etable.log 
 
echo "Running Tabling" 
mpirun -all-cpus -machinefile machines 
~/EGAD_Clients/bin/MPIPolymerTable --CLPLoad=etable.cmdline &> 
etable.log & 
 
echo "The script should be running, I'm printing the log file as it is 
written." 
echo "push CTRL+C to escape" 
 
tail -f etable.log 
Top5.pml 
load solution_0.pdb 
load solution_1.pdb 
load solution_2.pdb 
load solution_3.pdb 
load solution_4.pdb 
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# The interesting bits happen here: 
remove hydrogen 
#load the mutated residues 
sele 
/solution_0///147+159+214+215+216+217+221+223+290+292+294+209+210+211+2
12+148 
create Sol_0Mut, sele 
delete sele 
sele 
/solution_1///147+159+214+215+216+217+221+223+290+292+294+209+210+211+2
12+148 
create Sol_1Mut, sele 
delete sele 
sele 
/solution_2///147+159+214+215+216+217+221+223+290+292+294+209+210+211+2
12+148 
create Sol_2Mut, sele 
delete sele 
sele 
/solution_3///147+159+214+215+216+217+221+223+290+292+294+209+210+211+2
12+148 
create Sol_3Mut, sele 
delete sele 
sele 
/solution_4///147+159+214+215+216+217+221+223+290+292+294+209+210+211+2
12+148 
create Sol_4Mut, sele 
delete sele 
#load and select interesting residues 
#sele ////187+148+160+167+225 
#create Pocket, sele 
#delete sele 
show surface 
hide lines 
delete sele 
create Sol_0Dox, /solution_0///DOX 
create Sol_1Dox, /solution_1///DOX 
create Sol_2Dox, /solution_2///DOX 
create Sol_3Dox, /solution_3///DOX 
create Sol_4Dox, /solution_4///DOX 
show spheres, Sol_0Dox 
show spheres, Sol_1Dox 
show spheres, Sol_2Dox 
show spheres, Sol_3Dox 
show spheres, Sol_4Dox 
show dots, Sol_0Dox 
show dots, Sol_1Dox 
show dots, Sol_2Dox 
show dots, Sol_3Dox 
show dots, Sol_4Dox 
show sticks, Mutated 
#show surface, Pocket 
show spheres, DOX 
sele ////223 
create Switch, sele 
color red, Switch 
show sticks, Switch 
132 
delete sele 
load ../1f1J.pdb 
align 1f1j, solution_0 
hide lines, 1f1j 
hide sticks, 1f1j 
show cartoon, 1f1j 
delete sele 
sele /1f1j///223+523 
create 1F1J_Tyr, sele 
delete sele 
color blue, 1F1J_Tyr 
show sticks, 1F1J_Tyr 
load dox.pdb 
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